Novel substituted fluorinated vinyl-n-propyl-pyrrolidine compounds, process for their preparation and therapeutic use thereof

By developing fluorinated vinyl-N-propyl-pyrrolidine derivative compounds, the resistance of estrogen receptor antagonists and degradants in the prior art in the treatment of ERα-positive breast cancer is solved, and the estrogen is achieved The efficient degradation of receptors provides a new method for the treatment of ERα-positive breast cancer.

CN119032079APending Publication Date: 2024-11-26SANOFI SA(FR)
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202380033884.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-15
Filing Date
2023-04-14
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Existing estrogen receptor antagonists and degradants have resistance problems in the treatment of ERα-positive breast cancer and lack selective estrogen receptor degradants with good degradation effects.

Method used

A novel fluorinated vinyl-N-propyl-pyrrolidine derivative compound was developed to serve as an anticancer agent by selective antagonism and degradation of estrogen receptors. This compound can effectively inhibit ERα signaling and is used in the treatment of cancer treatment, especially breast cancer.

Benefits of technology

This compound significantly degrades estrogen receptors and shows efficient degradation activity. It can degrade 50% of the estrogen receptor concentration in in vitro experiments with IC50 less than 1μM, demonstrating its potential efficacy in the treatment of ERα-positive breast cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119032079A_ABST
    Figure CN119032079A_ABST
Patent Text Reader

Abstract

Disclosed herein are compounds of Formula (I) or pharmaceutically acceptable salts thereof: wherein R1 and R2 represent hydrogen or deuterium; r3 represents hydrogen,-COOH or-OH; r3'and R3 ''represent hydrogen, methyl, methoxyl, chlorine, fluorine or cyano; r4 and R4'represent hydrogen or fluorine; r5 represents hydrogen, fluorine or a (C1-C3) alkyl group; r6 represents a phenyl group, a fused phenyl group, a bicyclic group comprising 5 to 12 carbon atoms, a heteroaryl group comprising 2 to 9 carbon atoms and comprising from 1 to 3 heteroatoms, a cycloalkyl group comprising 3 to 7 carbon atoms, a (C3-C6) cycloalkyl (C1-C3) alkyl group, a 4 to 7 membered heterocycloalkyl group comprising 1 or 2 heteroatoms, a (C1-C6) alkyl group, and a phenyl (C1-C2) alkyl group; x represents-CH2-,-O-, or-S-; y represents-CH =,-N =, or-CR ''=; wherein R ''represents a (C1-C3) alkyl group, a halogen, a cyano group, or a (C1-C3) fluoroalkyl group; r7 represents a (C1-C3) alkyl group, a halogen atom, a cyano group, or a (C1-C3) fluoroalkyl group; r8 represents hydrogen or fluorine; r9 represents hydrogen, a (C1-C3) alkyl group, or a cyclopropyl group; n is 0, 1 or 2; and m is 0 or 1. Further disclosed are processes for preparing the same, pharmaceutical compositions comprising the same and the compounds of formula (I) for use as inhibitors and degrading agents of estrogen receptors, in particular in the treatment of ovulation dysfunction, cancer, endometriosis, osteoporosis, benign prostatic hyperplasia or inflammation. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Disclosed herein are novel fluorinated vinyl-N-propyl-pyrrolidine derivatives, methods for their preparation, and their therapeutic uses, particularly as anticancer agents via selective antagonism and degradation of estrogen receptors.

[0002] Estrogen receptor (ER) belongs to the steroid / nuclear receptor superfamily that participates in regulating differentiation in eukaryotic gene expression, cell proliferation and target tissues. ER is in two forms: estrogen receptor α (ERα) and estrogen receptor β (ERβ) encoded by ESR1 and ESR2 genes, respectively. ERα and ERβ are ligand-activated transcription factors, which are activated by the hormone estrogen (the most potent estrogen produced in vivo is 17β-estradiol). In the absence of hormones, ER is mainly located in the cytosol of cells. When the hormone estrogen binds to ER, ER migrates from the cytosol of cells to the nucleus, forms a dimer, and then binds to a specific genomic sequence called an estrogen response element (ERE). DNA / ER complexes interact with co-regulators to regulate the transcription of target genes.

[0003] ERα is mainly expressed in reproductive tissues such as uterus, ovary, breast, bone and white adipose tissue. Abnormal ERα signaling leads to the development of a variety of diseases such as cancer, metabolic and cardiovascular diseases, neurodegenerative diseases, inflammatory diseases and osteoporosis.

[0004] ERα is expressed in no more than 10% of normal breast epithelium, but is expressed in approximately 50%-80% of breast tumors. Such breast tumors with high levels of ERα are classified as ERα-positive breast tumors. The etiological role of estrogen in breast cancer is established, and regulation of ERα signaling remains the mainstay of breast cancer treatment for most ERα-positive breast tumors. Currently, there are several strategies for inhibiting the estrogen axis in breast cancer, including: 1-blocking estrogen synthesis through aromatase inhibitors for the treatment of early and late ERα-positive breast cancer patients; 2-antagonizing estrogen ligand binding to ERα through tamoxifen for the treatment of ERα-positive breast cancer patients in both premenopausal and postmenopausal situations; 3-antagonizing and downregulating ERα levels through Fulvestrant for the treatment of breast cancer in patients who have progressed despite endocrine therapy such as tamoxifen or aromatase inhibitors.

[0005] Although these endocrine therapies have greatly contributed to the reduction of breast cancer development, about more than one-third of ERα-positive patients show resistance to such existing therapies from the beginning or develop resistance over time. Several mechanisms have been described to explain resistance to such hormone therapies. For example, the hypersensitivity of ERα to low estrogen levels in the treatment with aromatase inhibitors, the switching of tamoxifen effects from antagonists to agonist effects or multiple growth factor receptor signaling pathways in tamoxifen treatment. ERα acquired mutations that occur after the start of hormone therapy may also play a role in treatment failure and cancer progression. Certain mutations in ERα, particularly those identified in the ligand binding domain (LBD), lead to the ability to bind to DNA in the absence of a ligand and confer hormone independence in cells with such mutant receptors.

[0006] Most of the identified mechanisms of resistance to endocrine therapy rely on ERα-dependent activity. One of the new strategies to combat this resistance is to shut down ERα signaling by removing ERα from tumor cells using selective estrogen receptor degraders (SERDs). Clinical and preclinical data suggest that a number of resistance pathways can be circumvented by using SERDs.

[0007] There remains a need to provide SERDs with good degradation efficacy.

[0008] Documents WO2017 / 140669 and WO2018 / 091153 disclose some substituted 6,7-dihydro-5H-benzo[7]annulene compounds and substituted N-(3-fluoropropyl)-pyrrolidine derivatives that can be used as SERDs.

[0009] The inventors have now discovered novel compounds capable of selectively antagonizing and degrading estrogen receptors (SERD compounds) for use in cancer treatment.

[0010] Disclosed herein are compounds of formula (I) or pharmaceutically acceptable salts thereof:

[0011]

[0012] in:

[0013] - R1 and R2 independently represent a hydrogen atom or a deuterium atom;

[0014] -R3 represents a hydrogen atom, a -COOH group or a -OH group;

[0015] - R3' and R3" independently represent a hydrogen atom, a methyl group, a methoxy group, a chlorine atom, a fluorine atom or a cyano group;

[0016] - R4 and R4' independently represent a hydrogen atom or a fluorine atom;

[0017] -R5 represents a hydrogen atom, a fluorine atom or a (C1-C3) alkyl group;

[0018] -R6 represents a group selected from the following:

[0019] ■ phenyl, which is optionally substituted by 1 to 3 substituents independently selected from the group consisting of a halogen atom; a (C1-C6)alkyl group optionally substituted by a cyano group or an -OH group; a (C1-C6)fluoroalkyl group; a (C3-C6)cycloalkyl group; a (C1-C6)alkoxy group; a (C1-C6)fluoroalkoxy group; a cyano group; a trifluoromethylsulfonyl group; a (C1-C4)alkylthio group; a (C1-C4)fluoroalkylthio group; a (C1-C4)alkylsulfonyl group and an -OH group;

[0020] ■ a fused phenyl group selected from a phenyl group fused to a (C3-C6)cycloalkyl group, the (C3-C6)cycloalkyl group optionally comprising unsaturation, and wherein the fused phenyl group is optionally substituted with 1 to 3 substituents independently selected from a (C1-C3)alkyl group, a hydroxyl group, a halogen atom, a (C1-C6)fluoroalkyl group, and a (C1-C3)alkoxy group;

[0021] ■ a bicyclic group containing 5 to 12 carbon atoms, optionally containing 1 to 2 degrees of unsaturation; optionally substituted by 1 to 4 substituents independently selected from the group consisting of fluorine atoms, -OH groups, (C1-C3)alkyl groups, (C1-C3)fluoroalkyl groups, (C1-C3)alkoxy groups, (C1-C3)fluoroalkoxy groups and oxo groups;

[0022] ■ a heteroaryl group containing 2 to 9 carbon atoms and containing from 1 to 3 heteroatoms independently selected from oxygen, nitrogen and sulfur and at least 5 atoms including carbon atoms and heteroatoms, such as a pyridyl group, which is optionally substituted by 1 to 3 substituents independently selected from halogen atoms, (C1-C6)alkyl, (C1-C6)fluoroalkyl, (C1-C6)alkoxy, (C1-C6)fluoroalkoxy, cyano, carbamoyl and -OH groups;

[0023] ■ a cycloalkyl group containing 3 to 7 carbon atoms, which is saturated or partially saturated and optionally substituted with 1 to 4 substituents independently selected from:

[0024] o fluorine atom, -OH group, (C1-C3) alkyl group, (C1-C3) fluoroalkyl group, (C1-C3) alkoxy group, (C1-C3) fluoroalkoxy group, oxo group,

[0025] o (C3-C6) cycloalkyl and phenyl, wherein the (C3-C6) cycloalkyl or phenyl is optionally substituted by one or two halogen atoms or (C1-C3) alkyl;

[0026] ■ (C3-C6)cycloalkyl (C1-C3)alkyl, which is optionally substituted on the cycloalkyl by 1 to 4 substituents independently selected from the group consisting of a fluorine atom, an -OH group, a (C1-C4)alkyl group, a (C1-C3)fluoroalkyl group, a (C1-C3)fluoroalkoxy group and an oxo group;

[0027] ■ 4- to 7-membered heterocycloalkyl containing 1 or 2 heteroatoms independently selected from oxygen, nitrogen and sulfur, such as tetrahydropyranyl, which is saturated or partially saturated and optionally substituted by 1 to 3 substituents independently selected from the group consisting of fluorine atoms, (C1-C3)alkyl, (C1-C3)fluoroalkyl, (C1-C3)fluoroalkoxy, oxo, (C1-C3)alkoxy and -OH groups;

[0028] ■ (C1-C6) alkyl, such as isobutyl, methyl or ethyl, optionally substituted with 1 to 4 substituents independently selected from the group consisting of fluorine atoms, (C1-C3) alkoxy, (C1-C3) fluoroalkoxy and -OH groups; and

[0029] ■phenyl(C1-C2)alkyl, the phenyl being optionally substituted by 1 to 3 substituents independently selected from the group consisting of: halogen atoms; (C1-C3)alkyl; (C1-C3)fluoroalkyl; (C1-C3)alkoxy; (C1-C3)fluoroalkoxy; cyano; and -OH groups;

[0030] -X represents -CH2-, -O- or -S-;

[0031] -Y represents -CH=, -N= or -CR"=, wherein R" represents a (C1-C3)alkyl group, a halogen atom such as a fluorine or chlorine atom, a cyano group, or a (C1-C3)fluoroalkyl group such as a trifluoromethyl group;

[0032] - R7 independently represents a (C1-C3)alkyl group such as a methyl group, a halogen atom such as a fluorine atom, a cyano group, or a (C1-C3)fluoroalkyl group such as a trifluoromethyl group;

[0033] -R8 represents a hydrogen atom or a fluorine atom;

[0034] -R9 represents a hydrogen atom, a (C1-C3) alkyl group or a cyclopropyl group;

[0035] -n is 0, 1, or 2; and

[0036] -m is 0 or 1.

[0037] The compounds of formula (I) may contain one or more asymmetric carbon atoms and may therefore exist in the form of enantiomers.

[0038] The compounds of formula (I) may also exist in tautomeric forms.

[0039] The compound of formula (I) may exist in the form of a base, an acid, a zwitterion or an addition salt with an acid or a base. Accordingly, provided herein is a compound of formula (I) or a pharmaceutically acceptable salt thereof.

[0040] These salts may be prepared with pharmaceutically acceptable acids or bases, although salts of other acids or bases useful, for example, in the purification or isolation of compounds of formula (I) are also provided.

[0041] Among suitable salts of the compounds of formula (I), hydrochlorides may be cited.

[0042] As used herein, unless otherwise noted, the following terms have the following definitions throughout this specification:

[0043] - halogen atoms: fluorine, chlorine, bromine or iodine atoms, and in particular fluorine and chlorine atoms;

[0044] -Oxo: "=O" group;

[0045] - Alkyl: a straight or branched saturated hydrocarbon aliphatic group, which, unless otherwise specified, contains from 1 to 6 carbon atoms (indicated as "(C1-C6) alkyl"). By way of example, but not limited to: methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl and isohexyl, etc. may be mentioned;

[0046] - Cycloalkyl: saturated or partially unsaturated and unsubstituted or substituted monocyclic alkyl radicals, which, unless otherwise indicated, contain from 3 to 7 carbon atoms. By way of example, but not limited to, mention may be made of: cyclopropyl, cyclobutyl, cyclopentyl, cyclobutenyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl and cycloheptenyl, etc., in particular cyclopentyl, cyclohexyl or cyclohexenyl;

[0047] - Cycloalkylalkyl: alkyl substituted by a cyclic alkyl as defined above. Mention may be made, but is not limited to: cyclobutylmethyl;

[0048] - Heterocycloalkyl: saturated or partially unsaturated 4 to 7 membered cycloalkyl containing 1 to 2 heteroatoms independently selected from oxygen, nitrogen and sulfur, in particular oxygen or nitrogen. By way of example, but not limited to, mention may be made of: morpholinyl, piperazinyl, piperidinyl, pyrrolidinyl, aziridinyl, oxanyl, oxetanyl, tetrahydropyranyl, morpholinyl, tetrahydrofuranyl, oxetanyl, diazepanyl, dioxanyl, tetrahydropyranyl and tetrahydrothiopyranyl. Heterocycloalkyl is advantageously tetrahydropyranyl.

[0049] -Fluoroalkyl: an alkyl group as defined previously, wherein the alkyl group is substituted by at least one fluorine atom. In other words, at least one hydrogen atom of the alkyl group is replaced by a fluorine atom. By way of example, -CH2F, -CHF2, -CH2CHF2, -CH2CH2F, etc. may be mentioned. When all hydrogen atoms belonging to the alkyl group are replaced by fluorine atoms, the fluoroalkyl group may be named as a perfluoroalkyl group. By way of example, trifluoromethyl or trifluoroethyl, etc. may be mentioned, and in particular trifluoromethyl;

[0050] - Alkoxy: -O-alkyl, wherein alkyl is as defined previously. By way of example, but not limited to, there may be mentioned: methoxy; ethoxy; propoxy; isopropoxy; linear butoxy, sec-butoxy or tert-butoxy; isobutoxy; pentyloxy or hexyloxy, etc.;

[0051] -Fluoroalkoxy: -O-alkyl, wherein alkyl is as defined previously and wherein alkyl is substituted by at least one fluorine atom. In other words, at least one hydrogen atom of the alkyl is replaced by a fluorine atom. By way of example, -OCH2F, -OCHF2, -OCH2CH2F, etc. may be mentioned. When all hydrogen atoms belonging to the alkyl are replaced by fluorine atoms, the fluoroalkoxy may be named as perfluoroalkoxy. By way of example, trifluoromethoxy, etc. may be mentioned;

[0052] -(C1-C4)alkylthio, which is also named (C1-C4)alkylsulfanyl: -S-alkyl, wherein alkyl is as defined previously. By way of example, but not limited to, there may be mentioned: methylthio, ethylthio, propylthio, isopropylthio, straight-chain secondary or tert-butylthio, isobutylthio, etc.;

[0053] -(C1-C4)alkylsulfonyl: -SO2-alkyl, wherein alkyl is as defined above. By way of example, but not limited to, -SO2CH3,

[0054] -SO2CH2CH3, etc.

[0055] -(C1-C4)fluoroalkylthio, which is also named (C1-C4)fluoroalkylsulfanyl: -S-fluoroalkyl, wherein the fluoroalkyl group is as defined above. For example, there can be mentioned but are not limited to: fluoromethylthio, difluoromethylthio, trifluoromethylthio, etc.;

[0056] - Fused phenyl: a bicyclic radical comprising from 7 to 10 carbon atoms and containing a phenyl moiety. The phenyl moiety may be fused to a (C3-C6)cycloalkyl group, i.e. the phenyl moiety may share a bond with the (C3-C6)cycloalkyl group. The fused phenyl group may be bound to the rest of the molecule via its phenyl moiety. It may be substituted. Examples are, but are not limited to, indanyl, bicyclo[4.2.0]octa-1(6),2,4-trienyl, tetrahydronaphthyl, etc.;

[0057] -Heteroaryl: A 5- to 10-membered cyclic aromatic group containing 2 to 9 carbon atoms and 1 to 3 heteroatoms such as nitrogen, oxygen or sulfur. Such nitrogen atoms may be replaced by oxygen atoms to form -NO bonds. Such -NO bonds may be in the form of N-oxides (-N + -O - ) in the form of. The heteroaryl group may be monocyclic or bicyclic. As examples of heteroaryl groups, mention may be made, but is not limited to: thiophene, furan, thiadiazole, thiazole, imidazole, pyridazine, triazine, pyrazine, oxadiazole, pyrazole, isothiazole, oxazole, isoxazole, pyridine, pyrimidine, benzotriazole, benzoxazole, pyrrolo[2,3-b]pyridine, benzimidazole, benzooxadiazole, benzothiazole, benzothiadiazole, benzofuran, indole, isoquinoline, indazole, benzisoxazole, benzisothiazole, pyridone groups and the like. The heteroaryl group is advantageously pyridine, pyrrole, imidazole, pyrazine, furan, thiazole, pyrazole, thiadiazole, pyridazine, pyridone and pyrimidine, and more particularly pyridine;

[0058] - Bicyclic radicals generally containing from 5 to 12 carbon atoms are hydrocarbon radicals chosen from radicals containing two rings connected by:

[0059] · Single common atom: "spiro bicyclic". Such spiro bicyclic alkyl groups usually contain 5 to 11 carbon atoms and refer to "spiro (C5-C 11 The ring may be saturated or partially unsaturated. Such spiro bicyclic rings may be unsubstituted or substituted, in particular substituted by at least one (C1-C3)alkyl group such as methyl or fluorine. Regarding the definition of R6, as spiro (C5-C 11 ) Examples of bicyclic rings include, but are not limited to, spiro[2.3]hexane, spiro[3.3]heptane, spiro[3.3]heptene, spiro[2.5]octane and 7-azaspiro[3.5]nonane. Also for the R6 group, spiro(C5-C 11 ) the bicyclic ring is advantageously spiro[2.3]hexane, spiro[3.3]heptane or spiro[3.3]heptene;

[0060] Two common atoms: in this case, the bicyclic radical contains 7 to 12 carbon atoms and optionally contains 1 to 2 degrees of unsaturation. As examples of such bicyclic radicals, mention may be made, without limitation, of cis-1,3a,4,5,6,6a-hexahydropentenyl, bicyclo[3.1.0]hex-1-yl, bicyclo[4.1.0]heptanyl and octahydropentalenyl,

[0061] Three or more common atoms: In this case, the bicyclic group contains 6 to 10 carbon atoms and such a bicyclic group may be referred to as a "bridged (C6-C 10)cycloalkyl", the ring has three or more atoms in total and the bridge contains at least one atom, such as 1, 2 or 3 atoms and preferably 1 atom. As examples of such bridged cycloalkyl groups, mention may be made, but are not limited to, bicyclo[3.2.1]octan-3-yl and bicyclo[2.2.1]hept-2-yl.

[0062] - Zwitterion means: a generally neutral molecule having both positive and negative charges and possessing both acidic and basic groups.

[0063] In another embodiment, in the compounds of formula (I) as defined above, R1 and R2 are hydrogen atoms.

[0064] In another embodiment, in the compounds of formula (I) as defined above, R3 is a -COOH group.

[0065] In another embodiment, in the compounds of formula (I) as defined above, R3′ and R3″ both represent a hydrogen atom.

[0066] In another embodiment, in the compounds of formula (I) as defined above, X represents --CH2-.

[0067] In another embodiment, in the compound of formula (I) as defined above, R4 and R4' both represent hydrogen atoms, or one of R4 and R4' represents a hydrogen atom and the other represents a fluorine atom.

[0068] In another embodiment, in the compounds of formula (I) as defined above, R5 represents a hydrogen atom.

[0069] In another embodiment, in the compound of formula (I) as defined above, R represents a phenyl group, which is optionally substituted by 1 to 3 substituents independently selected from the following: halogen atoms; (C1-C6) alkyl and (C1-C6) fluoroalkyl, more particularly selected from chlorine atoms, fluorine atoms, methyl and trifluoromethyl. In such embodiments, in particular, at least one of the substituents of the phenyl group comprises a halogen atom.

[0070] In another embodiment, in the compounds of formula (I) as defined above, n is 0 or 1 and R7 is a fluorine atom.

[0071] In another embodiment, in the compounds of formula (I) as defined above, n is 0.

[0072] In another embodiment, in the compounds of formula (I) as defined above, Y represents -CH=.

[0073] In another embodiment, in the compounds of formula (I) as defined above, m is 1.

[0074] In another embodiment, in the compounds of formula (I) as defined above, m is 0.

[0075] In another embodiment, in the compounds of formula (I) as defined above, R3 is a -COOH group and R6 is a phenyl group comprising one, two or three, more particularly two, substituents independently selected from chlorine atoms, fluorine atoms, trifluoromethyl and methyl, at least one of the substituents comprising a halogen atom. In such an embodiment, R3' and R3" are particularly hydrogen atoms. Also in such an embodiment, R1, R2, R5, R8 and R9 are hydrogen atoms. In such an embodiment, R4 and R4' are both hydrogen atoms or one of R4 and R4' is a hydrogen atom and the other is a fluorine atom. Also in such an embodiment, Y is a -CH= group, m is equal to 1 and n is equal to 0. Also in such an embodiment, X is a -CH2- group.

[0076] Among the compounds of formula (I) described herein, the following compounds or their pharmaceutically acceptable salts, in particular their hydrochlorides, may be mentioned in particular:

[0077] -(Z)-8-(2,4-dichlorophenyl)-9-(4-((1-(3,3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride (1),

[0078] -(Z)-8-(2-chloro-4-fluorophenyl)-9-(4-((1-(3,3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid (2),

[0079] -(Z)-4-(2,4-dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-2,3-dihydrobenzo[b]oxepin -8-carboxylic acid hydrochloride (3),

[0080] -Z)-8-(2,4-dichlorophenyl)-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid (4),

[0081] -(Z)-8-(2,4-difluorophenyl)-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride (5),

[0082] -(Z)-8-(4-fluoro-2-methylphenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid (6),

[0083] -(Z)-3-(4-(8-(2-chlorophenyl)-6,7-dihydro-5H-benzo[7]annulene-9-yl)benzylidene)-1-(3-fluoropropyl)pyrrolidine (7),

[0084] -(Z)-8-(4-fluoro-2-(trifluoromethyl)phenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid (8),

[0085] -(Z)-8-(2,4-difluorophenyl)-9-(4-((1-(3,3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid (9),

[0086] -(Z)-8-(3-chloro-2-methylphenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid (10),

[0087] -(Z)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-8-(3-methyl-2-(trifluoromethyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid (11),

[0088] -(Z)-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-8-(3-methyl-2-(trifluoromethyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid (12),

[0089] -(Z)-8-(3-chloro-2-methylphenyl)-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid (13),

[0090] -(Z)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-8-(2-methyl-3-(trifluoromethyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid (14),

[0091] -(Z)-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-8-(4-fluoro-2-methylphenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid (15),

[0092] -(Z)-8-(2,4-dichlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-ol hydrochloride (16),

[0093] -(Z)-8-(2,4-dichlorophenyl)-9-(4-((1-(3-difluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-ol hydrochloride (17),

[0094] -(Z)-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-8-(4-fluoro-2-(trifluoromethyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid (18),

[0095] -(Z)-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-8-(2-methyl-3-(trifluoromethyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid (19),

[0096] -(Z)-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-8-(4-fluoro-2,6-dimethyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid (20),

[0097] -(Z)-8-(4-fluoro-2,6-dimethylphenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid (21),

[0098] -(Z)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-8-(2-(trifluoromethyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid (22),

[0099] -(Z)-8-(2,4-dichlorophenyl)-9-(3-fluoro-4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid (23),

[0100] -(Z)-6-(2,4-dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-7,8-dihydronaphthalene-2-carboxylic acid hydrochloride (24),

[0101] -(Z)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-8-(3-(trifluoromethyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid (25),

[0102] -(Z)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-8-(4-(trifluoromethyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid (26),

[0103] -(Z)-8-(3-chlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid (27),

[0104] -(Z)-8-(4-chlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid (28),

[0105] -(Z)-8-(4-fluoro-2,5-dimethylphenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid (29),

[0106] -(Z)-4-(2,4-dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-2,3-dihydrobenzo[b]thia -8-ol (30).

[0107] Another embodiment is a compound selected from the above list or a pharmaceutically acceptable salt thereof for use in therapy, especially as an inhibitor and degrader of estrogen receptors.

[0108] Another embodiment is a compound selected from the above list or a pharmaceutically acceptable salt thereof for use in the treatment of cancer, especially breast cancer.

[0109] Another embodiment is a method of inhibiting and degrading estrogen receptors, which comprises administering a therapeutically effective amount of a compound selected from the above list or a pharmaceutically acceptable salt thereof to a subject, especially a human, in need thereof.

[0110] Another embodiment is a method for treating ovulatory dysfunction, cancer, endometriosis, osteoporosis, benign prostatic hypertrophy or inflammation, comprising administering to a subject, particularly a human, in need thereof a therapeutically effective amount of a compound selected from the above list or a pharmaceutically acceptable salt thereof.

[0111] Another embodiment is a method of treating cancer, comprising administering to a subject, particularly a human, in need thereof a therapeutically effective amount of a compound selected from the above list or a pharmaceutically acceptable salt thereof.

[0112] Another embodiment is a pharmaceutical composition comprising, as an active ingredient, an effective dose of a compound selected from the above list or a pharmaceutically acceptable salt thereof, and also at least one pharmaceutically acceptable excipient.

[0113] The compound of formula (I) can be prepared by the following method.

[0114] Compounds of formula (I) and other related compounds with different substituents are synthesized using techniques and materials described below or otherwise known to those skilled in the art. In addition, the solvents, temperatures and other reaction conditions presented below may be varied as deemed appropriate by those skilled in the art.

[0115] The following general methods for preparing compounds of formula (I) optionally modified by using appropriate reagents and conditions for introducing the various moieties found in formula (I) are described below.

[0116] The following abbreviations and empirical formulas are used:

[0117] MeCN Acetonitrile

[0118] NH4Cl Ammonium chloride

[0119] CO Carbon monoxide

[0120] CO2 Carbon dioxide

[0121] Cs2CO3 Cesium carbonate

[0122] DBU 1,8-diazabicyclo[5.4.0]undec-7-ene

[0123] DCM Dichloromethane

[0124] Et2O Ether

[0125] DIEA Diisopropylethylamine

[0126] DMF N,N-Dimethylformamide

[0127] DMAP dimethylaminopyridine

[0128] DMSO Dimethyl sulfoxide

[0129] BOC2O Di-tert-butyl dicarbonate

[0130] EtOH

[0131] EtOAc Ethyl acetate

[0132] HCl

[0133] LiHMDS Lithium bis(trimethylsilyl)amide

[0134] LiOH Lithium Hydroxide

[0135] MeOH Methanol

[0136] MgSO4 Magnesium sulfate

[0137] MTBE Methyl tert-butyl ether

[0138] MeTHF 2-Methyltetrahydrofuran

[0139] n-BuLi n-butyllithium

[0140] KOAc Potassium acetate

[0141] KHMDS Potassium bis(trimethylsilyl)amide

[0142] K2CO3 Potassium carbonate

[0143] KOH Potassium Hydroxide

[0144] NaBH4 Sodium borohydride

[0145] NaHCO3 Sodium bicarbonate

[0146] NaH Sodium hydride

[0147] NaOH Sodium hydroxide

[0148] Na2SO4 Sodium sulfate

[0149] SCX Strong Cation Exchange

[0150] Pd(dppf)Cl2 [1,1′-bis(diphenylphosphino)ferrocene]palladium(II) chloride

[0151] Pd(PPh3)2Cl2 Bis(triphenylphosphine)palladium(II) dichloride

[0152] Pd2(dba)3 tris(dibenzylideneacetone)dipalladium(0)

[0153] PhOK Potassium Phenolate

[0154] SFC Supercritical Fluid Chromatography

[0155] TEA Triethylamine

[0156] TFA Trifluoroacetic acid

[0157] THF Tetrahydrofuran

[0158] PPh3 Triphenylphosphine

[0159] RT Room temperature

[0160] XANTPHOS (9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine). Scheme 1a - Part-1: Preparation of compounds of formula (I) - General method

[0161]

[0162] Option 1a – Part 2

[0163]

[0164] According to Scheme 1a - Part-1 and Part-2, wherein R3a is a hydrogen atom or a carboxylate such as COOMe, COOEt, or a protected OH such as O-pivaloyl, R6 is a phenyl or heteroaryl group; and R1, R2, R3, R3', R3", R4, R4', R5, R7, R8, R9, X, m, n and Y are as defined above, compound 1A can be prepared in step 1 by treating with an aryl or heteroaryl bromide or iodide in the presence of a palladium catalyst such as tris(dibenzylidene) acetone)dipalladium(0)Pd2(dba)3 and a phosphine such as (9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine) (XANTPHOS) in a solution in toluene or xylene by heating to solvent reflux in the presence of a base such as K2CO3 or Cs2CO3 to compound 1B. An alternative way to prepare compound 1B (wherein R6 can be any group as defined above for R6 in formula (I)) is described in Scheme 1e below.

[0165] Compound 1B can be converted to compound 1C in step 2 by treatment with N,N-bis(trifluoromethylsulfonyl)aniline in the presence of a base such as DBU or NaH, or KHMDS in a solvent such as MeTHF at -50 °C.

[0166] Compound 1C can be converted to compound 1E in step 4 by, for example, treating with bis(pinacolato)diboron and with a palladium catalyst such as bis(triphenylphosphine)palladium(II) dichloride Pd(PPh3)2Cl2 and a phosphine such as triphenylphosphine in toluene in a solution, by heating to solvent reflux in the presence of a base such as KOPh.

[0167] Compound 1K can be prepared in a Suzuki coupling reaction between compounds 1C and 1D in step 3 or between compounds 1E and 1F in step 5, using, for example, [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (Pd(dppf)Cl2) complexed with DCM as a catalyst, in a mixture of dioxane and water and in the presence of a base such as cesium carbonate (Cs2CO3) by heating to solvent reflux.

[0168] Alternatively, compound 1E can be converted to compound 1H in step 6 in a Suzuki coupling reaction with compound 1G using, for example, [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (Pd(dppf)Cl2) complexed with DCM as a catalyst in a mixture of dioxane and water and in the presence of a base such as cesium carbonate (Cs2CO3) by heating to solvent reflux. Compound 1H can be converted to compound 1I in step 7 by treatment with a solution of TFA in DCM or a solution of HCl in dioxane. Compound 1I can be converted to compound 1K in step 8 by treatment with compound 1J (wherein W is Br, I or OSO2R, where R═CH3, PhMe, CF3 or CF2CF2CF2CF3) in the presence of a base such as potassium carbonate at 70°C in DMF, or in the presence of sodium hydroxide or potassium hydroxide at room temperature in THF, or in the presence of aqueous sodium hydroxide in DCM at room temperature.

[0169] When R3a is COOMe, COOEt, or a protected OH such as O-pivaloyl, compound 1K can be deprotected to compound I in step 9 by treatment with an aqueous solution of sodium hydroxide (NaOH) or lithium hydroxide (LiOH) in MeOH. When R3 is COOH, extraction of the compound can afford the sodium salt of compound I. Acidification with an aqueous solution of HCl 2N to pH 6-7 can afford the neutral form. Acidification with an aqueous solution of HCl 2N to pH 1-2 can afford the hydrochloride. Purification using HPLC can afford the formate or trifluoroacetate salt.

[0170] Option 1b – Part-1 and Part-2 : Alternative Methods for Preparing Compounds of Formula (I) - General Methods

[0171] Option 1b – Part 1 :

[0172]

[0173] Option 1b – Part 2 :

[0174]

[0175] According to Scheme 1b - Part-1 and - Part-2, wherein R3a is a hydrogen atom, a carboxylate such as COOMe, COOEt, or a protected OH such as O-pivaloyl, R1, R2, R3, R3', R3", R4, R4', R6, R7, R8, R9, X, n, m and Y are as defined above, and R5 is a hydrogen atom, compound 1L can be converted to compound 1N in step 1 in a Suzuki coupling reaction with compound 1M using, for example, [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (Pd(dppf)Cl2) complexed with DCM as a catalyst in a mixture of dioxane and water and in the presence of a base such as Cs2CO3 by heating to solvent reflux.

[0176] Compound 1N can be converted to compound 10 in step 2 by treatment with pyridinium tribromide, for example in DCM or THF at room temperature.

[0177] Compound 10 can be converted to compound 1P in step 3 by treatment with a solution of sulfuric acid in water.

[0178] Compound 1P can be converted to compound 1Q in step 4 by, for example, treatment with bis(pinacolato)diboron and with a palladium catalyst such as bis(triphenylphosphine)palladium(II) dichloride Pd(PPh3)2Cl2 and a phosphine such as triphenylphosphine in toluene in a solution, by heating to solvent reflux in the presence of a base such as KOPh or AcOK.

[0179] Compound 1K can be prepared in a Suzuki coupling reaction between compound 1P and R6B(OR')2 or R6BF3K (wherein -B(OR')2 is a boronic acid or pinacol ester and R6 is as defined above) in step 5 or between compound 1Q and R6Br or R6I in step 6, using, for example, [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (Pd(dppf)Cl2) complexed with DCM as a catalyst in a mixture of dioxane and water and in the presence of a base such as cesium carbonate (Cs2CO3) by heating to solvent reflux.

[0180] An alternative way to prepare compound 1K, wherein R5 can be any group as defined above for R5 in formula (I), is described in Scheme 1f below.

[0181] Compound 1K can be converted to a compound of formula (I) in step 7 in the presence of a hydroxide ion source such as NaOH or LiOH in solution in MeOH.

[0182] Compound 1P can be converted to a compound of formula 1Pa in step 8 in the presence of a hydroxide ion source such as NaOH or LiOH in solution in MeOH.

[0183] This compound 1Pa can be converted to compound I in step 9 by Suzuki conditions using a suitable boronic acid reagent R6B(OR')2 or R6BF3K (wherein -B(OR')2 is a boronic acid or pinacol ester and R6 is as defined above), using, for example, Pd(dppf)Cl2 complexed with DCM as a catalyst, in a mixture of dioxane and water as solvent and in the presence of a base such as Cs2CO3, at room temperature or by heating to solvent reflux.

[0184] When R3a is COOMe, COOEt, or a protected OH such as O-pivaloyl, deprotection can be carried out in step 7 by treatment with an aqueous solution of NaOH 2N or LiOH in MeOH. When R3 is COOH, extraction of the product can afford the sodium or lithium salt of compound I. Acidification with an aqueous solution of HCl 2N to pH 6-7 can afford the neutral form of compound I. Acidification with an aqueous solution of HCl 2N to pH 1-2 can afford the hydrochloride salt of compound I. Purification using HPLC in the presence of formic acid or trifluoroacetic acid in the eluent can afford the formate or trifluoroacetate salt of compound I.

[0185] Solution 1c : Alternative Methods for Preparing Compounds of Formula (I) - General Methods

[0186]

[0187] According to Scheme 1c, wherein R3a is a hydrogen atom, a carboxylate such as COOMe, COOEt, or a protected OH such as O-pivaloyl, R1, R2, R3, R3', R3", R4, R4', R6, R7, R8, R9, X, n, m and Y are as defined above, and R5 is a hydrogen atom, compound 1C' can be converted to compound 1S in step 1 in a Suzuki coupling reaction with compound 1R using, for example, [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (Pd(dppf)Cl2) complexed with DCM as a catalyst in a mixture of dioxane and water and in the presence of a base such as Cs2CO3 by heating to solvent reflux.

[0188] Compound 1S can be converted to compound 1N in step 2 by, for example, treatment with NaBH 4 in a solvent such as MeOH.

[0189] Compound 1N can be converted to compound 10 in step 3 by treatment with pyridinium tribromide, for example in DCM or THF at room temperature.

[0190] Compound 1O can be converted to compound 1T in step 4 by Suzuki conditions using a suitable boronic acid reagent R6B(OR')2 or R6BF3K (wherein -B(OR')2 is a boronic acid or pinacol ester and R6 is as defined above), using, for example, [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (Pd(dppf)Cl2) complexed with DCM as a catalyst, in a mixture of dioxane and water and in the presence of a base such as Cs2CO3, by heating to solvent reflux.

[0191] Compound 1T can be converted to compound I by treatment with a hydroxide ion source such as NaOH or LiOH in solution in MeOH followed by treatment with sulfuric acid.

[0192] Scheme 1d : Preparation of compounds of formula (1A) (wherein R3a = CO2Me) - General method

[0193]

[0194] According to Scheme 1d, wherein X, m, R3', R3" and R9 are as defined above, compound 1A may be commercially available or prepared as follows: Compound 1U (commercially available or prepared according to WO 2017140669 and WO 2018091153) may be converted to compound 1V in step 1 by treatment with trifluoromethanesulfonic anhydride in a solution in DCM in the presence of pyridine as base.

[0195] Compound 1V can be converted to compound 1A in step 2 by carbonylation with carbon monoxide in the presence of a palladium catalyst such as [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complexed with DCM (Pd(dppf)Cl 2 ) in solution in DMF and MeOH.

[0196] Option 1e : Alternative preparation of compounds of formula (1B) - General method

[0197]

[0198] According to Scheme 1e, wherein R3a is a hydrogen atom, a carboxylate such as COOMe, COOEt, or a protected OH such as O-pivaloyl, and R3′, R3″, R9, R6, X and m are as defined above, compound 1B can alternatively be prepared as follows: Compound 1A can be converted to compound 1Aa in step 1 by treatment with pyridinium tribromide, for example in DCM or THF at room temperature.

[0199] Compound 1Aa can be converted to compound 1Ab in step 2 by deprotonation with a base such as LiHMDS in THF followed by treatment with acetic anhydride.

[0200] Compound 1Ac can be prepared in step 3 in a Suzuki coupling reaction between compound 1Ab and R6B(OR')2 or R6BF3K (wherein -B(OR')2 is a boronic acid or pinacol ester and R6 is as defined above) using, for example, [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (Pd(dppf)Cl2) complexed with DCM as a catalyst in a mixture of toluene and water and in the presence of a base such as cesium carbonate (Cs2CO3) by heating to solvent reflux.

[0201] Compound 1Ac can be converted to compound 1B in step 4, for example, by hydrolysis with aqueous HCl by heating in methanol and DCM.

[0202] Scheme 1f : Alternative preparation of compounds of formula (1K) - General method

[0203]

[0204] According to Scheme 1f, wherein R3a is a hydrogen atom or a carboxylate such as COOMe, COOEt, or a protected OH such as O-pivaloyl, and R1, R2, R3, R3', R3", R4, R4', R5, R6, R7, R8, R9, X, m, n and Y are as defined above, compound 1C can be converted to compound 1E in step 1 by, for example, treating with bis(pinacolato)diboron and with a palladium catalyst such as bis(triphenylphosphine)palladium(II) dichloride Pd(PPh3)2Cl2 and a phosphine such as triphenylphosphine in toluene in a solution, by heating to solvent reflux in the presence of a base such as KOPh.

[0205] Compound 1W can be prepared in a Suzuki coupling reaction between compounds 1E and 1R′ in step 2 or between compounds 1C and 1R in step 3, using, for example, [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (Pd(dppf)Cl2) complexed with DCM as a catalyst, in a mixture of dioxane and water and in the presence of a base such as cesium carbonate (Cs2CO3) by heating to solvent reflux.

[0206] Compound 1W can be converted to compound 1X in step 4 by treatment with an alkylmagnesium bromide in a solvent such as THF.

[0207] Compound 1X can be converted to compound 1K in step 5 by treatment with sulfuric acid in water.

[0208] Also provided herein is a process for preparing a compound of formula (I) as defined above, wherein the compound of formula 1K

[0209]

[0210] -- wherein R1, R2, R3', R3", R4, R4', R5, R6, R7, R8, R9, m, n, X and Y are as defined above, and R3a is a hydrogen atom, a carboxylate such as COOMe, COOEt, or a protected OH such as O-pivaloyl -- is converted to a compound of formula (I) in the presence of a hydroxide ion source such as NaOH or LiOH in solution in methanol, said step optionally being preceded by a step for obtaining compound 1K, wherein a compound of formula 1P is converted to a compound of formula (I) in the presence of a hydroxide ion source such as NaOH or LiOH in solution in methanol, wherein said step is optionally preceded by a step for obtaining compound 1K, wherein a compound of formula 1P is converted to a compound of formula (I) in the presence of a hydroxide ion source such as NaOH or LiOH in solution in methanol

[0211]

[0212] -- wherein R1, R2, R3', R3", R4, R4', R5, R6, R7, R8, R9, m, n, X and Y are as defined above and R3a is as defined above--

[0213] Subjected to Suzuki coupling with a boronic acid reagent R6-B(OR')2 or R6BF3K, wherein -B(OR')2 is a boronic acid or pinacol ester and R6 is as defined above.

[0214] Also provided herein is a process for preparing a compound of formula (I) as defined above, wherein a compound of formula 1Pa

[0215]

[0216] - wherein R1, R2, R3a, R3', R3", R4, R4', R5, R7, R8, R9, m, n, X and Y are as defined above - undergoes a Suzuki coupling with a boronic acid reagent R6B(OR')2 or R6BF3K - wherein -B(OR')2 is a boronic acid or a pinacol ester and R6 is defined above, said step optionally being preceded by a step for obtaining compound 1Pa, wherein a compound of formula 1P

[0217]

[0218] -- wherein R1, R2, R3', R3", R4, R4', R5, R7, R8, R9, m, n, X and Y are as defined above and R3a is as defined above--

[0219] The conversion to compound 1Pa is carried out in solution in methanol in the presence of a hydroxide ion source such as NaOH or LiOH.

[0220] Also provided herein is an intermediate compound selected from the compounds of Formula 1P, 1K and 1Pa, or any pharmaceutically acceptable salt thereof,

[0221]

[0222] wherein R1, R2, R3′, R3″, R4, R4′, R5, R7, R8, R9, m, n, X and Y are as defined above, and R3a is a hydrogen atom, a carboxylate such as COOMe, COOEt, or a protected OH such as O-pivaloyl.

[0223] Further provided herein are intermediate compounds of Formula 1F and 1D or any pharmaceutically acceptable salt thereof

[0224]

[0225] wherein R1, R2, R4, R4', R5, R7, R8, Y and n are as defined above.

[0226] The present application also describes an intermediate compound of Formula 1E or any pharmaceutically acceptable salt thereof

[0227]

[0228] wherein R3a, R3′, R3″, X, m, R6 and R9 are as defined above.

[0229] In another aspect, there is also provided herein a process for preparing a compound of formula (I), wherein R3 is a -COOH group, comprising a deprotection step of a compound of formula 1K as defined above, optionally followed by a purification step.

[0230] The purification step may, for example, consist of an acidification step (eg with aqueous hydrochloric acid) as shown in step 2 of Example 1 herein below.

[0231] At 400 and 500MHz 1 H NMR spectra were performed on Bruker Avance DRX-400 and Bruker Avance DPX-500 spectrometers, respectively, with chemical shifts (δ, in ppm) in the solvent dimethyl sulfoxide-d6 (d6-DMSO) referenced to 2.5 ppm at a temperature of 303 K. Coupling constants (J) are given in Hertz.

[0232] Liquid chromatography / mass spectrometry (LC / MS) was obtained on a UPLC Acquity Waters instrument using UV detection DAD 210-400 nm and fast Acquity UPLC CSH C18 1.7 μm, size 2.1x30 mm, mobile phase H2O+0.1% HCO2H / CH3CN+0.1% HCO2H, light scattering detector Sedere and SQD Waters mass spectrometer.

[0233] Tables 1a and 1b below contain specific compounds (names and structures) of formula (I) according to the present disclosure and their characterizations ( 1 H NMR and LC / MS / MS).

[0234] Table 1a :

[0235]

[0236]

[0237]

[0238]

[0239]

[0240]

[0241]

[0242] Table 1b :

[0243]

[0244]

[0245]

[0246]

[0247]

[0248]

[0249]

[0250]

[0251] The following examples describe the preparation of some of the compounds of formula (I) described herein. The quantities of the compounds exemplified below match those given in Tables 1a and 1b above. Unless otherwise specified, all reactions were carried out under an inert atmosphere.

[0252] In the following examples, when the origin of the starting product is not specified, it is understood that the product is a known compound.

[0253] Intermediates:

[0254] Intermediate 1: 9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0255]

[0256] A mixture of 9-(((trifluoromethyl)sulfonyl)oxy)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester (15 g, 42.82 mmol) (prepared according to WO 2017140669) in toluene (150 ml), Pd(PPh3)2Cl2 (1.53 g, 2.14 mmol), PPh3 (673.87 mg, 2.57 mmol), bis(pinacolato)diboron (13.38 g, 52.67 mmol) and PhOK (8.04 g, 60.80 mmol) was heated to 75 °C for 1.5 h. The yellow suspension turned orange and then brown. After cooling to room temperature, DCM (150 mL) and water (150 mL) were added and decanted through a hydrophobic column. The organic phase was concentrated under reduced pressure. The residue obtained was purified by flash chromatography eluting with a gradient of heptane / DCM from 85 / 15 to 20 / 80 to give 10.1 g (72%) of methyl 9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate as a white solid.

[0257] LC / MS(m / z,MH+):329

[0258] Intermediate 2: 8-(2,4-dichlorophenyl)-9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0259]

[0260] Intermediate 2 was prepared from 8-(2,4-dichlorophenyl)-9-(((trifluoromethyl)sulfonyl)oxy)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester (prepared according to WO2020 / 049153) according to a procedure similar to that for the preparation of Intermediate 1 to give 3.9 g (82%) of 8-(2,4-dichlorophenyl)-9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester as a white solid.

[0261] LC / MS(m / z,MH+):473

[0262] Intermediate 3: 8-(2,4-difluorophenyl)-9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0263]

[0264] Step 1: 6-(2,4-difluorophenyl)-5-oxo-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-carboxylic acid methyl ester

[0265]

[0266] Argon is bubbled in a mixture of 1-bromo-2,4-difluoro-benzene (6.63g, 34.37mmol), 5-oxo-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-methylformate (5g, 22.91mmol), KCO(12.67g, 91.66mmol) in toluene (40ml) for 10 minutes. After adding XANTPHOS (1.32g, 2.29mmol) and Pd(dba)(1.05g, 1.15mmol), the reaction mixture is heated to reflux for 72 hours. After cooling to room temperature, water (40ml) and DCM (40ml) are added. After decantation, the aqueous phase is washed three times with 40ml of DCM. The combined organic phase is dried over MgSO, filtered and concentrated under reduced pressure. The residue obtained was purified by flash chromatography eluting with a gradient of heptane / EtOAc from 100 / 00 to 90 / 10 to give 2.55 g (34%) of methyl 6-(2,4-difluorophenyl)-5-oxo-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-carboxylate.

[0267] LC / MS(m / z,MH+):331

[0268] Step 2: 8-(2,4-difluorophenyl)-9-(((trifluoromethyl)sulfonyl)oxy)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0269]

[0270] To a suspension of NaH (545 mg, 13.62 mmol, 60% weight purity) in Me-THF (22 ml) cooled at 5 ° C, DBU (277 mg, 0.27 ml, 1.82 mmol) was added, followed by a solution of 6-(2,4-difluorophenyl)-5-oxo-6,7,8,9-tetrahydrobenzo[7]annulene-2-carboxylic acid methyl ester (3 g, 9.08 mmol) and N,N-bis(trifluoromethylsulfonyl)aniline (4.2 g, 11.81 mmol) in THF (25 ml). The cooling bath was removed to allow the temperature to rise until room temperature. A mixture of acetic acid (0.4 ml) and water (32 ml) was added dropwise, followed by water (100 ml) and EtOAc (150 ml). After decantation, the organic phase was dried over MgSO4, filtered and concentrated under reduced pressure. The residue obtained was purified by flash chromatography eluting with DCM / heptane 50 / 50 to give 2.77 g (66%) of methyl 8-(2,4-difluorophenyl)-9-(((trifluoromethyl)sulfonyl)oxy)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate.

[0271] LC / MS(m / z,MH+):463

[0272] Step 3: 8-(2,4-difluorophenyl)-9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0273]

[0274] Step 3 of Intermediate 3 was prepared from 8-(2,4-difluorophenyl)-9-(((trifluoromethyl)sulfonyl)oxy)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate following a procedure similar to that of Intermediate 1 to afford 1.89 g (72%) of methyl 8-(2,4-difluorophenyl)-9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate.

[0275] LC / MS(m / z,MH+):441

[0276] Intermediate 4: 8-(2-methyl-4-fluorophenyl)-9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0277]

[0278] Step 1: 6-(2-methyl-4-fluorophenyl)-5-oxo-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-carboxylic acid methyl ester

[0279]

[0280] Step 1 of Intermediate 4 was prepared from 1-bromo-2-methyl-4-fluoro-benzene following a procedure similar to that of Step 1 of Intermediate 3 to give 700 mg (47%) of methyl 6-(2-methyl-4-fluorophenyl)-5-oxo-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-carboxylate.

[0281] LC / MS(m / z,MH+):327

[0282] Step 2: 8-(2-methyl-4-fluorophenyl)-9-(((trifluoromethyl)sulfonyl)oxy)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0283]

[0284] Step 2 of Intermediate 4 was prepared from methyl 6-(2-methyl-4-fluorophenyl)-5-oxo-6,7,8,9-tetrahydrobenzo[7]annulene-2-carboxylate following a procedure similar to that of Step 2 of Intermediate 3 to afford 7.86 g (82%) of methyl 8-(2-methyl-4-fluorophenyl)-9-(((trifluoromethyl)sulfonyl)oxy)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate.

[0285] LC / MS(m / z,MH+):459

[0286] Step 3: 8-(2-methyl-4-fluorophenyl)-9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0287]

[0288] Step 3 of Intermediate 4 was prepared from 8-(2-methyl-4-fluorophenyl)-9-(((trifluoromethyl)sulfonyl)oxy)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester following a procedure similar to that for Intermediate 1 to afford 3.93 g (43%) of 8-(2-methyl-4-fluorophenyl)-9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester.

[0289] LC / MS(m / z,MH+):437

[0290] Intermediate 5: (4-bromophenyl)-[1-(3-fluoropropyl)pyrrolidin-3-yl]methanol

[0291]

[0292] Step 1: (4-Bromophenyl)-pyrrolidin-3-yl-methanone, 2,2,2-trifluoroacetic acid

[0293]

[0294] To a solution of commercially available tert-butyl 3-(4-bromobenzoyl)pyrrolidine-1-carboxylate (20.3 g, 57.31 mmol) in DCM (100 ml) was added TFA (100 ml) dropwise, and the reaction mixture was stirred at room temperature for 30 minutes. The reaction mixture was concentrated under reduced pressure and the obtained residue was triturated with Et2O. The formed solid was filtered to give 17 g (81%) of (4-bromophenyl)-pyrrolidin-3-yl-methanone, 2,2,2-trifluoroacetic acid.

[0295] LC / MS(m / z,MH+):254

[0296] Step 2: (4-Bromophenyl)-[1-(3-fluoropropyl)pyrrolidin-3-yl]methanone

[0297]

[0298] A mixture of (4-bromophenyl)-pyrrolidin-3-yl-methanone, 2,2,2-trifluoroacetic acid (9.45 g, 25.67 mmol), K2CO3 (10.64 g, 77 mmol), 1-fluoro-3-iodo-propane (5.07 g, 26.95 mmol) in MeCN (200 ml) was heated at 80° C. for 3 h. The reaction mixture was quenched by the addition of a saturated solution of NH4Cl (200 ml) and extracted with EtOAc (3×200 ml). The organic phase was washed with brine (200 ml), dried over Na2SO4, filtered and concentrated under reduced pressure, and the residue obtained was purified by flash chromatography eluting with a gradient of DCM / MeOH from 100 / 00 to 50 / 50 to 90 / 10 to give 6.34 g (78%) of (4-bromophenyl)-[1-(3-fluoropropyl)pyrrolidin-3-yl]methanone.

[0299] LC / MS(m / z,MH+):314

[0300] Step 3: (4-bromophenyl)-[1-(3-fluoropropyl)pyrrolidin-3-yl]methanol

[0301]

[0302] To a mixture of (4-bromophenyl)-[1-(3-fluoropropyl)pyrrolidin-3-yl]methanone (6.31 g, 20.07 mmol) in MeOH (180 ml) was added NaBH4 (2.28 g, 60.21 mmol) and the mixture was stirred at room temperature for 2 hours. A concentrated solution of NH4Cl (100 ml) and EtOAc (300 ml) were added. After decantation, the organic phase was washed with brine (200 ml), dried over Na2SO4, filtered and concentrated under reduced pressure to give 6.69 g (crude) of (4-bromophenyl)-[1-(3-fluoropropyl)pyrrolidin-3-yl]methanol.

[0303] LC / MS(m / z,MH+):316

[0304] Intermediate 6: 3-[(4-bromophenyl)methylene]-1-(3-fluoropropyl)pyrrolidine cis isomer

[0305]

[0306] At 0 ° C, sulfuric acid (35 ml) was added dropwise to a mixture of (4-bromophenyl)-[1-(3-fluoropropyl)pyrrolidin-3-yl]methanol (intermediate 5) (5.16 g, 16.33 mmol) and water (10 ml). The cooling bath was removed and the reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was poured into a mixture of ice and water (500 ml). Powdered NaHCO was added to pH 9. EtOAc (300 ml) was added and the organic phase was dried over Na2SO4, filtered, concentrated under reduced pressure, and the obtained residue was purified by flash chromatography with a gradient elution of DCM / EtOAc from 100 / 00 to 00 / 100 to obtain 4.13 g (85%) of 3-[(4-bromophenyl)methylene]-1-(3-fluoropropyl)pyrrolidine as a mixture of cis and trans isomers.

[0307] A mixture of cis and trans isomers of 3-[(4-bromophenyl)methylene]-1-(3-fluoropropyl)pyrrolidine was separated by preparative SFC using an IF 5x25cm, 5μm column (Daicel) and a CO2 mobile phase with 30% of 0.1% TEA in MeOH solution as a co-solvent. The temperature was set at 40°C and the back pressure regulator was set at 100 bar to give 1145 mg of the cis isomer (3Z)-3-[(4-bromophenyl)methylene]-1-(3-fluoropropyl)pyrrolidine and 2584 mg of the trans isomer (3E)-3-[(4-bromophenyl)methylene]-1-(3-fluoropropyl)pyrrolidine.

[0308] LC / MS(m / z,MH+):298

[0309] Intermediate 7: (4-bromophenyl)-[1-(3,3-difluoropropyl)pyrrolidin-3-yl]methanol

[0310]

[0311] Step 1: 3,3-Difluoropropyl 4-methylbenzenesulfonate

[0312]

[0313] To a solution of 3,3-difluoropropan-1-ol (500mg, 5.20mmol) in THF (10ml) cooled at 0°C, NaH (229mg, 5.72mmol, 60% by mass) was added. After stirring at 0°C for 1 hour, 4-methylbenzenesulfonyl chloride (1.03g, 4.13mmol) was added, and the reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was quenched by adding a saturated solution of NH4Cl (20ml) and extracted with EtOAc (3×20ml). The organic phase was washed with brine (20ml), dried over Na2SO4, filtered and concentrated under reduced pressure, and the obtained residue was purified by flash chromatography eluting with DCM to obtain 1.03g (79%) of 3,3-difluoropropyl 4-methylbenzenesulfonate.

[0314] LC / MS(m / z,MH+):251

[0315] Step 2: (4-Bromophenyl)-[1-(3,3-difluoropropyl)pyrrolidin-3-yl]methanone

[0316]

[0317] Step 2 of Intermediate 7 was prepared following a procedure similar to that of Step 2 of Intermediate 5 from (4-bromophenyl)-pyrrolidin-3-yl-methanone, 2,2,2-trifluoroacetic acid and 3,3-difluoropropyl 4-methylbenzenesulfonate to give 6.29 g (70%) of (4-bromophenyl)-[1-(3,3-difluoropropyl)pyrrolidin-3-yl]methanone.

[0318] LC / MS(m / z,MH+):332

[0319] Step 3: (4-Bromophenyl)-[1-(3,3-difluoropropyl)pyrrolidin-3-yl]methanol

[0320]

[0321] Step 3 of Intermediate 7 was prepared following a procedure similar to that of Step 3 of Intermediate 5 from (4-bromophenyl)-[1-(3,3-difluoropropyl)pyrrolidin-3-yl]methanone to give 5.53 g (crude) of (4-bromophenyl)-[1-(3,3-difluoropropyl)pyrrolidin-3-yl]methanol.

[0322] LC / MS(m / z,MH+):334

[0323] Intermediate 8: 3-[(4-bromophenyl)methylene]-1-(3,3-difluoropropyl)pyrrolidine cis isomer

[0324]

[0325] Intermediate 8 was prepared from (4-bromophenyl)-[1-(3,3-difluoropropyl)pyrrolidin-3-yl]methanol (Intermediate 7) following a procedure similar to that of Intermediate 6 to give 2.71 g (64%) of 3-[(4-bromophenyl)methylene]-1-(3,3-difluoropropyl)pyrrolidine as a mixture of cis and trans isomers.

[0326] A mixture of cis and trans isomers of 3-[(4-bromophenyl)methylene]-1-(3-fluoropropyl)pyrrolidine was separated by preparative SFC using an IG 5x25cm, 5μm column (Daicel) and a CO2 mobile phase with 30% of 0.1% TEA in MeOH solution as a co-solvent. The temperature was set at 40°C and the back pressure regulator was set at 100 bar to give 158 mg of the cis isomer (3Z)-3-[(4-bromophenyl)methylene]-1-(3,3-difluoropropyl)pyrrolidine and 299 mg of the trans isomer (3E)-3-[(4-bromophenyl)methylene]-1-(3,3-difluoropropyl)pyrrolidine.

[0327] LC / MS(m / z,MH+):316

[0328] Intermediate 9: (Z)-8-bromo-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0329]

[0330] Step 1: 9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)(hydroxy)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0331]

[0332] A mixture of 9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester (Intermediate 1) (3.42, 10.44 mmol), (4-bromophenyl)-[1-(3-fluoropropyl)pyrrolidin-3-yl]methanol (Intermediate 5) (3 g, 9.49 mmol), CsCO (8.04 g, 24.67 mmol), Pd(dppf)Cl (466 mg, 0.57 mmol) complexed with DCM in dioxane (24 ml) and water (6 ml) was heated to reflux for 1 hour. The reaction mixture was quenched by adding a saturated solution of NHCl (50 ml) and extracted with EtOAc (3×50 ml). The organic phase was washed with brine (50 ml), dried over Na2SO4, filtered and concentrated under reduced pressure, and the obtained residue was subjected to flash chromatography eluting with a gradient of DCM / MeOH from 100 / 00 to 80 / 20 to give 2.59 g (62%) of methyl 9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)(hydroxy)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate.

[0333] LC / MS(m / z,MH+):438

[0334] Step 2: 8-Bromo-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)(hydroxy)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0335]

[0336] To a mixture of 9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)(hydroxy)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester (2.60 g, 5.94 mmol) in DCM (100 ml) was added pyridinium tribromide (2.66 g, 8.31 mmol). The reaction mixture was stirred at room temperature for 18 hours. The reaction was quenched with a concentrated solution of NaHCO3 (100 ml) and DCM (150 ml). The organic phase was dried over Na2SO4, filtered, concentrated under reduced pressure and the obtained residue was purified by flash chromatography eluting with a gradient of DCM / MeOH from 100 / 00 to 80 / 20 to give 1.53 g (50%) of 8-bromo-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)(hydroxy)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester.

[0337] LC / MS(m / z,MH+):516

[0338] Step 3: (Z)-8-Bromo-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0339]

[0340] At 0°C, sulfuric acid (7 ml) was added dropwise to a mixture of 8-bromo-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)(hydroxy)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester (1.53 g, 2.97 mmol) and water (2 ml). The cooling bath was removed and the reaction mixture was stirred at room temperature for 30 minutes. The reaction mixture was poured into a mixture of ice and water (150 ml). Powdered NaHCO was added to pH 9. EtOAc (100 ml) was added and the organic phase was dried over Na2SO4, filtered, concentrated under reduced pressure and the residue obtained was purified by flash chromatography eluting with a gradient of DCM / EtOAc from 100 / 00 to 100 / 100 to afford 1.04 g (69%) of 8-bromo-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester as a mixture of cis- and trans-isomers.

[0341] A mixture of cis and trans isomers of methyl 8-bromo-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate was separated by preparative SFC using an IB-N55x25cm, 5μm column (Daicel) and CO2 mobile phase with 23% of 0.1% TEA in MeOH solution as co-solvent. The temperature was set at 40 °C and the back pressure regulator was set at 100 bar to give 170 mg of the cis isomer (Z)-8-bromo-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester and 388 mg of the trans isomer (E)-8-bromo-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester.

[0342] LC / MS(m / z,MH+):498

[0343] Intermediate 10: (Z)-8-bromo-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0344]

[0345] Step 1: 9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-yl)(hydroxy)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0346]

[0347] Step 1 of Intermediate 10 was prepared following a procedure analogous to that of Step 1 of Intermediate 9 from methyl 9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate (Intermediate 1) and (4-bromophenyl)-[1-(3,3-difluoropropyl)pyrrolidin-3-yl]methanol (Intermediate 7) to afford 5.98 g (80%) of methyl 9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-yl)(hydroxy)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate.

[0348] LC / MS(m / z,MH+):456

[0349] Step 2: 8-Bromo-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-yl)(hydroxy)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0350]

[0351] Step 2 of Intermediate 10 was prepared following a procedure similar to that of Step 2 of Intermediate 9 from methyl 9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-yl)(hydroxy)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate to afford 3.93 g (56%) of methyl 8-bromo-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-yl)(hydroxy)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate.

[0352] LC / MS(m / z,MH+):534

[0353] Step 3: (Z)-8-Bromo-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0354]

[0355] Step 3 of Intermediate 10 was prepared following a procedure similar to that of Step 3 of Intermediate 9 from methyl 8-bromo-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-yl)(hydroxy)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate to afford 2.46 g (65%) of methyl 8-bromo-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate as a mixture of cis and trans isomers.

[0356] A mixture of cis and trans isomers of methyl 8-bromo-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate was purified by chiral chromatography: Chiralpak AD 20 μM (250x 4.6 mm) was separated by elution with heptane / EtOH / TEA: 50 / 50 / 0.1 to give 562 mg of the cis isomer (Z)-8-bromo-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester and 986 mg of the trans isomer (E)-8-bromo-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester.

[0357] LC / MS(m / z,MH+):516

[0358] Intermediate 11: 2-(8-(2-chlorophenyl)-6,7-dihydro-5H-benzo[7]annulene-9-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane

[0359]

[0360] Step 1: 6-(2-Chlorophenyl)-6,7,8,9-tetrahydro-5H-benzo[7]annulene-5-one

[0361]

[0362] Step 1 of Intermediate 11 was prepared from 1-bromo-2-chloro-benzene and 6,7,8,9-tetrahydrobenzo[7]annulene-5-one following a procedure similar to that of Step 1 of Intermediate 3 to give 580 mg (16%) of 6-(2-chlorophenyl)-6,7,8,9-tetrahydro-5H-benzo[7]annulene-5-one.

[0363] LC / MS(m / z,MH+):271

[0364] Step 2: 8-(2-Chlorophenyl)-6,7-dihydro-5H-benzo[7]annulene-9-yl trifluoromethanesulfonate

[0365]

[0366] Step 2 of Intermediate 11 was prepared from 6-(2-chlorophenyl)-6,7,8,9-tetrahydro-5H-benzo[7]annulene-5-one following a procedure analogous to that of Step 2 of Intermediate 3 to give 608 mg (71%) of 8-(2-chlorophenyl)-6,7-dihydro-5H-benzo[7]annulene-9-yl trifluoromethanesulfonate.

[0367] LC / MS(m / z,MH+):403

[0368] Step 3: 2-(8-(2-chlorophenyl)-6,7-dihydro-5H-benzo[7]annulene-9-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane

[0369]

[0370] Step 3 of Intermediate 11 was prepared from 8-(2-chlorophenyl)-6,7-dihydro-5H-benzo[7]annulene-9-yl trifluoromethanesulfonate following a procedure similar to that of Intermediate 1 to give 430 mg (84%) of 2-(8-(2-chlorophenyl)-6,7-dihydro-5H-benzo[7]annulene-9-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane.

[0371] LC / MS(m / z,MH+):381

[0372] Intermediate 12: 4-(2,4-dichlorophenyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydrobenzo[b]oxepin -8-Methyl formate

[0373]

[0374] Step 1: 5-Oxo-2,3,4,5-tetrahydrobenzo[b]oxepin -8-yl trifluoromethanesulfonate

[0375]

[0376] 8-Hydroxy-3,4-dihydrobenzo[b]oxepin cooled at -20°C -5 (2H) -one (4.2g, 23.57mmol) (prepared according to WO 2018091153) and pyridine (2.82g, 2.89ml, 35.36mmol) in DCM (120ml) was added dropwise trifluoromethanesulfonic anhydride (8.14g, 6ml, 28.28mmol). The reaction mixture was stirred at 0 ° C for 30 minutes. Water (50ml) was added. The organic phase was separated and washed with a saturated aqueous solution of NaHCO (50ml). The organic phase was dried over MgSO, filtered, and concentrated under reduced pressure to obtain 7.40g (crude) of 5-oxo-2,3,4,5-tetrahydrobenzo [b] oxepin -8-yl trifluoromethanesulfonate.

[0377] LC / MS(m / z,MH+):311

[0378] Step 2: 5-Oxo-2,3,4,5-tetrahydrobenzo[b]oxepin -8-Methyl formate

[0379]

[0380] To the compound 5-oxo-2,3,4,5-tetrahydrobenzo[b]oxepin To a solution of -8-yl trifluoromethanesulfonate (7.4 g, 23.85 mmol) in DMF (30 ml) and MeOH (15 ml) was added DIEA (3.15 g, 4.16 ml, 23.85 mmol) and Pd(dppf)Cl2 (1.10 g, 1.43 mmol) complexed with DCM, the suspension was degassed and purged with CO three times. The mixture was stirred at 75 ° C for 2 hours under CO (5 bar). The reaction was filtered through diatomaceous earth. The filtrate was diluted with water (400 ml) and extracted three times with EtOAc (300 ml). The combined organic phases were dried over Na2SO4, filtered, concentrated under reduced pressure, and the obtained residue was purified by flash chromatography with a gradient elution of heptane / ethyl acetate from 85 / 15 to 80 / 20 to obtain 4.6 g (88%) of 5-oxo-2,3,4,5-tetrahydrobenzo[b]oxepin -8-Methyl formate.

[0381] LC / MS(m / z,MH+):221

[0382] Step 3: 4-(2,4-dichlorophenyl)-5-oxo-2,3,4,5-tetrahydrobenzo[b]oxepin -8-Methyl formate

[0383]

[0384] Following a procedure similar to that of Step 1 to prepare Intermediate 3, 5-oxo-2,3,4,5-tetrahydrobenzo[b]oxepin was prepared from Step 3 of the preparation of intermediate 12 to give 1.13 g (67%) of 4-(2,4-dichlorophenyl)-5-oxo-2,3,4,5-tetrahydrobenzo[b]oxepin -8-Methyl formate.

[0385] LC / MS(m / z,MH+):365

[0386] Step 4: 4-(2,4-dichlorophenyl)-5-(((trifluoromethyl)sulfonyl)oxy)-2,3-dihydrobenzo[b]oxepin -8-Methyl formate

[0387]

[0388] Following a procedure similar to that of Step 2 in the preparation of Intermediate 3, 4-(2,4-dichlorophenyl)-5-oxo-2,3,4,5-tetrahydrobenzo[b]oxepin was prepared from Step 4 of the preparation of intermediate 12 to give 0.48 g (31%) of 4-(2,4-dichlorophenyl)-5-(((trifluoromethyl)sulfonyl)oxy)-2,3-dihydrobenzo[b]oxepin -8-Methyl formate.

[0389] LC / MS(m / z,MH+):496

[0390] Step 5: 4-(2,4-dichlorophenyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydrobenzo[b]oxepin -8-Methyl formate

[0391]

[0392] Following a procedure similar to that for the preparation of Intermediate 1, 4-(2,4-dichlorophenyl)-5-(((trifluoromethyl)sulfonyl)oxy)-2,3-dihydrobenzo[b]oxepin was prepared. Step 5 of the preparation of intermediate 12 to give 260 mg (61%) of 4-(2,4-dichlorophenyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydrobenzo[b]oxepin -8-Methyl formate.

[0393] LC / MS(m / z,MH+):271

[0394] Intermediate 13: 8-(2,4-dichlorophenyl)-9-(((trifluoromethyl)sulfonyl)oxy)-6,7-dihydro-5H-benzo[7]annulene-3-yl pivalate

[0395]

[0396] Step 1: 6-(2,4-dichlorophenyl)-2-methoxy-6,7,8,9-tetrahydro-5H-benzo[7]annulene-5-one

[0397]

[0398] A mixture of 1-bromo-2,4-dichloro-benzene (890 mg, 3.94 mmol), 2-methoxy-6,7,8,9-tetrahydro-5H-benzo[7]annulene-5-one (500 mg, 2.63 mmol), XANTPHOS (0.304 g, 0.53 mmol) and Pd(dba) (0.3 g, 0.53 mmol) in xylene (10 ml) was heated to reflux for 16 hours. After cooling to room temperature, water (50 ml) and EtO (50 ml) were added. The organic phase was dried over MgSO, filtered and concentrated under reduced pressure. The residue obtained was purified by flash chromatography eluting with a gradient of cyclohexane / EtOAc from 100 / 00 to 95 / 05 to give 470 mg (42%) of 6-(2,4-dichlorophenyl)-2-methoxy-6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-one.

[0399] LC / MS(m / z,MH+):335

[0400] Step 2: 6-(2,4-dichlorophenyl)-2-hydroxy-6,7,8,9-tetrahydro-5H-benzo[7]annulene-5-one

[0401]

[0402] A mixture of 6-(2,4-dichlorophenyl)-2-methoxy-6,7,8,9-tetrahydro-5H-benzo[7]annulene-5-one (470mg, 1.23mmol) and aluminum chloride (395mg, 2.96mmol) in toluene (8ml) was heated at 90°C for 2 hours. After cooling to room temperature, water (20ml) and EtOAc (50ml) were added. The organic phase was dried over MgSO4, filtered and concentrated under reduced pressure. The obtained residue was purified by flash chromatography with a gradient elution of cyclohexane / EtOAc from 100 / 00 to 80 / 20 to obtain 165mg (42%) of 6-(2,4-dichlorophenyl)-2-hydroxy-6,7,8,9-tetrahydro-5H-benzo[7]annulene-5-one.

[0403] LC / MS(m / z,MH+):321

[0404] Step 3: 6-(2,4-dichlorophenyl)-5-oxo-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-yl pivalate

[0405]

[0406] A mixture of 6-(2,4-dichlorophenyl)-2-hydroxy-6,7,8,9-tetrahydro-5H-benzo[7]annulene-5-one (163 mg, 0.51 mmol), KCO (77 mg, 0.56 mmol) and pivaloyl chloride (67 mg, 0.56 mmol) in acetone (5 ml) was heated at 40° C. for 1 hour. After cooling to room temperature, the reaction mixture was filtered. The filtrate was concentrated under reduced pressure and the obtained residue was purified by flash chromatography with a gradient of cyclohexane / EtOAc from 100 / 00 to 90 / 10 to give 205 mg (96%) of 6-(2,4-dichlorophenyl)-5-oxo-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-yl pivalate.

[0407] LC / MS(m / z,MH+):405

[0408] Step 4: 8-(2,4-dichlorophenyl)-9-(((trifluoromethyl)sulfonyl)oxy)-6,7-dihydro-5H-benzo[7]annulene-3-yl pivalate

[0409]

[0410] Under Ar atmosphere, at -50 ° C, KHMDS (1M, 0.58 ml, 0.58 mmol) was added to a solution of 6-(2,4-dichlorophenyl)-5-oxo-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-yl pivalate (197 mg, 0.48 mmol) in THF (5 ml). The mixture was stirred for 30 min, and 1,1,1-trifluoro-N-phenyl-N-(trifluoromethylsulfonyl) methanesulfonamide (173 mg, 0.49 mmol) was added to the resulting mixture. The reaction mixture was slowly warmed to 20 ° C and stirred for 90 minutes. The reaction mixture was quenched with saturated citric acid aqueous solution, then diluted with water and extracted twice with Et2O. The combined organic layer was dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography with a gradient of cyclohexane / EtOAc from 100 / 00 to 90 / 10 to give 160 mg (61%) of 8-(2,4-dichlorophenyl)-9-(((trifluoromethyl)sulfonyl)oxy)-6,7-dihydro-5H-benzo[7]annulen-3-yl pivalate.

[0411] LC / MS(m / z,MH+):537

[0412] Intermediate 14: (3Z)-1-(3-fluoropropyl)-3-[[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methylene]pyrrolidine

[0413]

[0414] A mixture of (3Z)-3-[(4-bromophenyl)methylene]-1-(3-fluoropropyl)pyrrolidine (intermediate 6) (200 mg, 0.67 mmol) in dioxane (4 ml), Pd(PPh3)2Cl2 (38 mg, 0.07 mmol), bis(pinacolato)diboron (221 mg, 0.87 mmol) and AcOK (164 mg, 1.68 mmol) was heated under reflux for 2 hours. After cooling, the reaction mixture was filtered on celite. The filtrate was concentrated under reduced pressure and the residue was purified by flash chromatography eluting with a gradient of DCM / EtOAc / EtOH from 100 / 00 / 00 to 75 / 20 / 05 to give 160 mg (69%) of (3Z)-1-(3-fluoropropyl)-3-[[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methylene]pyrrolidine.

[0415] LC / MS(m / z,MH+):346

[0416] Intermediate 15: (3Z)-1-(3,3-difluoropropyl)-3-[[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methylene]pyrrolidine

[0417]

[0418] Intermediate 15 was prepared from (3Z)-3-[(4-bromophenyl)methylene]-1-(3,3-difluoropropyl)pyrrolidine (Intermediate 8) following a procedure analogous to that for Intermediate 14 to afford 114.8 mg (87%) of (3Z)-1-(3,3-difluoropropyl)-3-[[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methylene]pyrrolidine.

[0419] LC / MS(m / z,MH+):364

[0420] Intermediate 16: 6-(2,4-dichlorophenyl)-5-(trifluoromethylsulfonyloxy)-7,8-dihydronaphthalene-2-carboxylic acid methyl ester

[0421]

[0422] Step 1: 2-(2,4-Dichlorophenyl)-1-oxo-tetralin-6-carboxylic acid methyl ester

[0423]

[0424] Step 1 of Intermediate 16 was prepared from methyl 1-oxotetralin-6-carboxylate following a procedure similar to that of Step 1 of Intermediate 3 to afford 459 mg (19%) of 4-(2,4-dichlorophenyl)-5-oxo-2,3,4,5-tetrahydrobenzo[b]oxepin. -8-Methyl formate.

[0425] LC / MS(m / z,MH+):349

[0426] Step 2: Methyl 6-(2,4-dichlorophenyl)-5-(trifluoromethylsulfonyloxy)-7,8-dihydronaphthalene-2-carboxylate

[0427]

[0428] Step 2 of Intermediate 16 was prepared following a procedure similar to that of Step 2 of Intermediate 3 from 2-(2,4-dichlorophenyl)-1-oxo-tetralin-6-carboxylic acid methyl ester to give 0.48 g (31%) of methyl 6-(2,4-dichlorophenyl)-5-(trifluoromethylsulfonyloxy)-7,8-dihydronaphthalene-2-carboxylate.

[0429] LC / MS(m / z,MH+):481

[0430] Intermediate 17: (Z)-3-(4-bromo-2-fluorobenzylidene)-1-(3-fluoropropyl)pyrrolidine

[0431]

[0432] Step 1: tert-Butyl 3-(4-bromo-2-fluorobenzoyl)pyrrolidine-1-carboxylate

[0433]

[0434] n-BuLi 2.5M (18ml, 44.52mmol) was added dropwise to a solution of 1,4-dibromo-2-fluoro-benzene (11.3g, 44.52mmol) in THF (60ml) cooled at -78°C. After stirring for 45 minutes at -78°C, a solution of 3-[methoxy(methyl)carbamoyl]pyrrolidine-1-carboxylic acid tert-butyl ester (10g, 38.71mmol) in THF (60ml) was added dropwise. The cooling bath was removed and the reaction mixture was stirred at room temperature for 18 hours. The reaction mixture was poured into a mixture of saturated NH4Cl aqueous solution (200ml) and EtOAc (300ml). After decantation, the organic layer was dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography with a gradient of DCM / EtOAc from 100 / 0 to 80 / 20 to give 2.27 g (13%) of tert-butyl 3-(4-bromo-2-fluorobenzoyl)pyrrolidine-1-carboxylate.

[0435] LC / MS(m / z,MH+):372

[0436] Step 2: (4-bromo-2-fluorophenyl)(pyrrolidin-3-yl)methanone, 2,2,2-trifluoroacetic acid

[0437]

[0438] Step 2 of Intermediate 17 was prepared following a procedure analogous to that of Step 1 of Intermediate 5 from tert-butyl 3-(4-bromo-2-fluorobenzoyl)pyrrolidine-1-carboxylate to afford 1.96 g (84%) of (4-bromo-2-fluorophenyl)(pyrrolidin-3-yl)methanone, 2,2,2-trifluoroacetic acid.

[0439] LC / MS(m / z,MH+):272

[0440] Step 3: (4-bromo-2-fluorophenyl)(1-(3-fluoropropyl)pyrrolidin-3-yl)methanone

[0441]

[0442] Step 3 of Intermediate 17 was prepared following a procedure analogous to that of Step 2 of Intermediate 5 from (4-bromo-2-fluorophenyl)(pyrrolidin-3-yl)methanone, 2,2,2-trifluoroacetic acid to afford 1.13 g (67%) of (4-bromo-2-fluorophenyl)(1-(3-fluoropropyl)pyrrolidin-3-yl)methanone.

[0443] LC / MS(m / z,MH+):332

[0444] Step 4: (4-bromo-2-fluorophenyl)(1-(3-fluoropropyl)pyrrolidin-3-yl)methanol

[0445]

[0446] Step 4 of Intermediate 17 was prepared following a procedure analogous to that of Step 3 of Intermediate 5 from (4-bromo-2-fluorophenyl)(1-(3-fluoropropyl)pyrrolidin-3-yl)methanone to afford 2.1 g (97%) of (4-bromo-2-fluorophenyl)(1-(3-fluoropropyl)pyrrolidin-3-yl)methanol.

[0447] LC / MS(m / z,MH+):334

[0448] Step 5: (Z)-3-(4-bromo-2-fluorobenzylidene)-1-(3-fluoropropyl)pyrrolidine

[0449]

[0450] Step 5 of Intermediate 17 was prepared following a procedure similar to that of Intermediate 6 from (4-bromo-2-fluorophenyl)(1-(3-fluoropropyl)pyrrolidin-3-yl)methanol to give 925 mg of 3-(4-bromo-2-fluorobenzylidene)-1-(3-fluoropropyl)pyrrolidine as a mixture of cis and trans isomers.

[0451] A mixture of cis and trans isomers of 3-(4-bromo-2-fluorobenzylidene)-1-(3-fluoropropyl)pyrrolidine was purified by chiral chromatography: Chiralpak AD 20 μm (250 x 4.6 mm) eluted with heptane / EtOH / TEA: 95 / 05 / 0.1 to give 510 mg of the trans isomer (E)-3-(4-bromo-2-fluorobenzylidene)-1-(3-fluoropropyl)pyrrolidine and 248 mg of the cis isomer (Z)-3-(4-bromo-2-fluorobenzylidene)-1-(3-fluoropropyl)pyrrolidine.

[0452] LC / MS(m / z,MH+):316

[0453] Intermediate 18: [1-(3-fluoropropyl)pyrrolidin-3-yl]-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methanone

[0454]

[0455] Intermediate 18 was prepared from (4-bromophenyl)-[1-(3-fluoropropyl)pyrrolidin-3-yl]methanone (step 2 of Intermediate 5) following a procedure similar to that for Intermediate 14 to give 2.4 g (100%) of [1-(3-fluoropropyl)pyrrolidin-3-yl]-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methanone.

[0456] LC / MS(m / z,MH+):362

[0457] Method A:

[0458] Example 1 :(Z)-8-(2,4-dichlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, hydrochloride

[0459]

[0460] Step 1: (Z)-8-(2,4-dichlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0461]

[0462] A mixture of 8-(2,4-dichlorophenyl)-9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester (Intermediate 2) (261.8 mg, 0.23 mmol), (3Z)-3-[(4-bromophenyl)methylene]-1-(3-fluoropropyl)pyrrolidine (Intermediate 6) (150 mg, 0.50 mmol), Cs2CO3 (426 mg, 1.31 mmol) and Pd(dppf)Cl2 complexed with DCM (25.8 mg, 0.03 mmol) in dioxane (4 ml) and water (1 ml) was heated to reflux for 1 hour. After cooling to room temperature, water (10 ml) and EtOAc (20 ml) were added. After decantation, the organic phase was dried over Na2SO4, filtered, concentrated under reduced pressure and the residue obtained was purified by flash chromatography eluting with cyclohexane / EtOAc 50 / 50 to give 131 mg (46%) of (Z)-8-(2,4-dichlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester.

[0463] LC / MS(m / z,MH+):564

[0464] Step 2: (Z)-8-(2,4-dichlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, hydrochloride

[0465]

[0466] To a solution of (Z)-8-(2,4-dichlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester (131 mg, 0.22 mmol) in MeOH (2 ml), THF (1 ml) and water (0.5 ml) was added LiOH (53.86 mg, 2.25 mmol) and the reaction mixture was stirred at room temperature for 24 hours. The reaction mixture was concentrated under reduced pressure. To the obtained residue was added water (and HCl 1N until pH 1-2. The solid formed was filtered, washed with Et2O and dried to give 81.5 mg (62%) of (Z)-8-(2,4-dichlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, hydrochloride.

[0467] Method B:

[0468] Example 2 :(Z)-8-(2-chloro-4-fluorophenyl)-9-(4-((1-(3,3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid

[0469]

[0470] Step 1: (Z)-8-(2-chloro-4-fluorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0471]

[0472] A mixture of (Z)-8-bromo-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester (Intermediate 9) (87 mg, 0.17 mmol), (2-chloro-4-fluoro-phenyl)boronic acid (36.5 mg, 0.21 mmol), CsCO (148 mg, 0.45 mmol) and Pd(dppf)Cl (8.55 mg, 0.01 mmol) complexed with DCM in dioxane (4 ml) and water (1 ml) was heated under reflux for 1 hour. After cooling to room temperature, the reaction mixture was quenched with a saturated solution of NHCl (5 ml) and EtOAc (20 ml). After decantation, the organic phase was dried over Na2SO4, filtered, concentrated under reduced pressure, and the residue was purified by flash chromatography eluting with a gradient of DCM / MeOH from 100 / 00 to 80 / 20 to give 53 mg (55%) of (Z)-8-(2-chloro-4-fluorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester.

[0473] LC / MS(m / z,MH+):548

[0474] Step 2: (Z)-8-(2-chloro-4-fluorophenyl)-9-(4-((1-(3,3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid

[0475]

[0476] Step 2 of Example 2 was prepared according to a procedure similar to that of Step 2 of Preparative Example 1 from (Z)-8-(2-chloro-4-fluorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester to give 33 mg (66%) of (Z)-8-(2-chloro-4-fluorophenyl)-9-(4-((1-(3,3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid.

[0477] Method C:

[0478] Example 24 :(Z)-6-(2,4-dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-7,8-dihydronaphthalene-2-carboxylic acid, hydrochloride

[0479]

[0480] Step 1: (Z)-6-(2,4-dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-7,8-dihydronaphthalene-2-carboxylic acid methyl ester

[0481]

[0482] A mixture of methyl 6-(2,4-dichlorophenyl)-5-(trifluoromethylsulfonyloxy)-7,8-dihydronaphthalene-2-carboxylate (Intermediate 16) (280 mg, 0.28 mmol), (3Z)-1-(3-fluoropropyl)-3-[[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methylene]pyrrolidine (Intermediate 14) (151 mg, 0.44 mmol), CsCO (486 mg, 1.49 mmol) and Pd(dppf)Cl complexed with DCM (43 mg, 0.05 mmol) in dioxane (3 ml) and water (1.21 ml) was heated at reflux for 30 minutes. After cooling to room temperature, water (2 ml) and DCM (10 ml) were added. After decanting on a hydrophobic column, the organic phase was dried over Na2SO4, filtered, concentrated under reduced pressure and the residue obtained was purified by flash chromatography eluting with a gradient of DCM / MeOH from 100 / 00 to 95 / 05 to give 123 mg (51%) of (Z)-6-(2,4-dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-7,8-dihydronaphthalene-2-carboxylic acid methyl ester.

[0483] LC / MS(m / z,MH+):550

[0484] Step 2: (Z)-6-(2,4-dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-7,8-dihydronaphthalene-2-carboxylic acid, hydrochloride

[0485]

[0486] Step 2 of Example 24 was prepared according to a procedure similar to that of Step 2 of Preparative Example 1 from (Z)-6-(2,4-dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-7,8-dihydronaphthalene-2-carboxylic acid methyl ester to give 113 mg (88%) of (Z)-6-(2,4-dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-7,8-dihydronaphthalene-2-carboxylic acid, hydrochloride.

[0487] Method D:

[0488] Example 16 :(Z)-8-(2,4-dichlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-ol, hydrochloride

[0489]

[0490] Step 1: (Z)-8-(2,4-dichlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-yl pivalate

[0491]

[0492] A mixture of 8-(2,4-dichlorophenyl)-9-(((trifluoromethyl)sulfonyl)oxy)-6,7-dihydro-5H-benzo[7]annulene-3-yl pivalate (Intermediate 13) (60 mg, 0.11 mmol), (3Z)-1-(3-fluoropropyl)-3-[[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methylene]pyrrolidine (Intermediate 14) (40 mg, 0.11 mmol), CsCO (91 mg, 0.28 mmol) and Pd(dppf)Cl complexed with DCM (6 mg, 0.008 mmol) in dioxane (2 ml) and water (0.51 ml) was heated to reflux for 30 minutes. After cooling to room temperature, water (5 ml) and EtOAc (10 ml) were added. After decantation, the organic phase was dried over Na2SO4, filtered, concentrated under reduced pressure and the residue obtained was purified by flash chromatography eluting with a gradient of cyclohexane / EtOAc from 90 / 10 to 80 / 20 to give 31 mg (46%) of (Z)-8-(2,4-dichlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-yl pivalate.

[0493] LC / MS(m / z,MH+):607

[0494] Step 2: (Z)-8-(2,4-dichlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-ol, hydrochloride

[0495]

[0496] To a solution of (Z)-8-(2,4-dichlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-ylpivalate (31 mg, 0.04 mmol) in MeOH (2 ml) was added NaOH (6.8 mg, 0.17 mmol), and the reaction mixture was stirred at room temperature for 30 minutes. The reaction mixture was concentrated under reduced pressure. Water (5 ml) and HCl 1N were added to the obtained residue until pH 1-2, followed by DCM (10 ml). After decantation, the organic phase was dried over Na2SO4, filtered, concentrated under reduced pressure and the residue obtained was purified by flash chromatography eluting with a gradient of DCM / MeOH from 100 / 00 to 95 / 05 to give 5.6 mg (17%) of (Z)-8-(2,4-dichlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-ol, hydrochloride.

[0497] Method E:

[0498] Example 30 :(Z)-4-(2,4-dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-2,3-dihydrobenzo[b]thia -8-ol

[0499]

[0500] Step 1: 5-(4-(1-(3-fluoropropyl)pyrrolidine-3-carbonyl)phenyl)-2,3-dihydrobenzo[b]thia -8-aminopivalate

[0501]

[0502] Following a procedure similar to that of Step 1 of Preparative Example 16, 5-(((trifluoromethyl)sulfonyl)oxy)-2,3-dihydrobenzo[b]thiazole was prepared. -8-yl pivalate (prepared according to WO 2018091153) and [1-(3-fluoropropyl)pyrrolidin-3-yl]-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methanone (Intermediate 18) Step 1 of Preparation Example 30 to obtain 2.7 g (86%) of 5-(4-(1-(3-fluoropropyl)pyrrolidine-3-carbonyl)phenyl)-2,3-dihydrobenzo[b]thiamethoxam -8-yl pivalate.

[0503] LC / MS(m / z,MH+):496

[0504] Step 2: 5-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)(hydroxy)methyl)phenyl)-2,3-dihydrobenzo[b]thiazole -8-aminopivalate

[0505]

[0506] Following a procedure analogous to that of Step 3 in the preparation of Intermediate 5, 5-(4-(1-(3-fluoropropyl)pyrrolidine-3-carbonyl)phenyl)-2,3-dihydrobenzo[b]thiazolidine was prepared from Step 2 of Preparation Example 30 to obtain 980 mg (36%) of 5-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)(hydroxy)methyl)phenyl)-2,3-dihydrobenzo[b]thiamine -8-yl pivalate.

[0507] LC / MS(m / z,MH+):498

[0508] Step 3: 4-Bromo-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)(hydroxy)methyl)phenyl)-2,3-dihydrobenzo[b]thiazole -8-aminopivalate

[0509]

[0510] Following a procedure analogous to that of step 2 to prepare intermediate 9, 5-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)(hydroxy)methyl)phenyl)-2,3-dihydrobenzo[b]thiazole was prepared. Step 3 of Preparation Example 30 to obtain 650 mg (56%) of 4-bromo-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)(hydroxy)methyl)phenyl)-2,3-dihydrobenzo[b]thiazol-8-yl pivalate -8-yl pivalate.

[0511] LC / MS(m / z,MH+):576

[0512] Step 4: 4-(2,4-dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)(hydroxy)methyl)phenyl)-2,3-dihydrobenzo[b]thia -8-aminopivalate

[0513]

[0514] According to the procedure similar to that of Step 1 of Preparation Example 2, 4-bromo-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)(hydroxy)methyl)phenyl)-2,3-dihydrobenzo[b]thiazole was prepared. Step 4 of Preparation Example 30 was used to obtain 700 mg (97%) of 4-(2,4-dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)(hydroxy)methyl)phenyl)-2,3-dihydrobenzo[b]thiazol-8-yl pivalate. -8-yl pivalate.

[0515] LC / MS(m / z,MH+):642

[0516] Step 5: 4-(2,4-dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)(hydroxy)methyl)phenyl)-2,3-dihydrobenzo[b]thia -8-ol

[0517]

[0518] To 4-(2,4-dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)(hydroxy)methyl)phenyl)-2,3-dihydrobenzo[b]thiazole -8-yl pivalate (724mg, 1.09mmol) in MeOH (5ml) solution add NaOH5N (0.65ml, 3.3mmol), and reaction mixture is stirred at room temperature for 30 minutes.Reaction mixture is concentrated under reduced pressure.In the residue obtained, add water (5ml) and HCl 1N until pH 7, then add DCM (20ml).After decantation, organic phase is through Na2SO4 drying, filter, concentrate under reduced pressure, and the residue obtained is purified by flash chromatography with the gradient elution of DCM / MeOH from 100 / 00 to 90 / 10 to obtain 570mg (91%) of 4-(2,4-dichlorophenyl)-5-(4-((1-(3-fluoropropyl) pyrrolidin-3-yl) (hydroxy) methyl) phenyl)-2,3-dihydrobenzo [b] thia -8-ol.

[0519] LC / MS(m / z,MH+):558

[0520] Step 5: (Z)-4-(2,4-dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-2,3-dihydrobenzo[b]thia -8-ol

[0521]

[0522] To 4-(2,4-dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)(hydroxy)methyl)phenyl)-2,3-dihydrobenzo[b]thiamine cooled at 0°C was added -8- alcohol (560mg, 1mmol) in water (1.3ml) is dropwise added sulfuric acid (11ml, 207mmol). Remove cooling bath, and the reaction mixture is stirred at room temperature for 18 hours and at 50 ° C for 1.5 hours. The reaction mixture is poured into a mixture of ice and water (500ml). Add powdered NaHCO to pH 9, then add EtOAc (300ml), and the organic phase is separated and dried over Na2SO4, filtered, concentrated under reduced pressure, and the residue is purified by flash chromatography with a gradient elution of DCM / MeOH from 100 / 00 to 95 / 05 to obtain 11mg (2%) of 4-(2,4-dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolidine-3-ylidene)methyl)phenyl)-2,3-dihydrobenzo[b]thia -8-ol.

[0523] 4-(2,4-dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-2,3-dihydrobenzo[b]thia The mixture of (Z) and (E) isomers of -8-ol was separated on a column I-Cellulose 5 μm (equivalent to phenomenex Chiralpak IC) (0.3×25 cm) eluted with heptane / EtOH / TEA (90 / 10 / 0.1) to give 2.7 mg of the (Z) isomer (Z)-4-(2,4-dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-2,3-dihydrobenzo[b]thiapiperidin -8-ol and 4.1 mg of the (E) isomer (E)-4-(2,4-dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-2,3-dihydrobenzo[b]thiazol -8-ol.

[0524] The compounds according to Table 1a above were subjected to pharmacological testing for determining their degradation effect on the estrogen receptor.

[0525] Test: Estrogen receptor degradation activity

[0526] The test involves measuring the in vitro degradation activity of the compounds of Table 1a.

[0527] Degradation activity of ERα was measured using breast cancer cells in a cellular Western blot assay as described below.

[0528] MCF7 cells (ATCC) were seeded in red phenol-free MEMα medium (Invitrogen) containing 5% activated carbon dextran treated fetal bovine serum (FBS) at a concentration of 10,000 cells / 30 μL / well in 384-well microplates (collagen coated). The next day, 9 points of each compound were added to the cells in a final concentration ranging from 0.3-0.0000018 μM (Table 2) or 0.1 μM of Fulvestrant (used as a positive control) in 2.5 μL cells: 1:5 dilutions were added to the cells. 4 hours after compound addition, cells were fixed by adding 25 μL of formalin (5% formalin with a final concentration of 0.1% triton) for 10 minutes at room temperature, and then washed twice with PBS. Then, 50 μL of LI-COR blocking buffer containing 0.1% Triton was added to the plate for 30 minutes at room temperature. LI-COR blocking buffer was removed and cells were incubated overnight in a cold room with 50 μL of anti-ER rabbit monoclonal antibody (Thermo scientific MA1-39540) diluted 1:1000 in LI-COR blocking buffer containing 0.1% tween-20. Wells treated with blocking buffer but without antibody were used as background controls. The wells were washed twice with PBS (0.1% tween-20) and incubated at 37°C for 60 minutes in LI-COR (0.1% tween-20) containing goat anti-rabbit antibody Alexa 488 (1:1000) and Syto-64a DNA dye (2 μM final concentration). The cells were then washed 3 times in PBS and scanned in an ACUMEN detector (TTP-Labtech). The integrated intensity of green and red fluorescence was measured to determine the levels of ERα and DNA, respectively.

[0529] In this test, the degradation activity of estrogen receptor is determined by the concentration that degrades 50% of the estrogen receptor (or IC 50 ) is given in nM.

[0530] The % reduction in ERa levels was determined as follows: % inhibition = 100*(1-(sample - fulvestrant:DMSO-fulvestrant)).

[0531] The following Table 2 shows the estrogen receptor degradation activity results of the compounds of Table 1a tested at 0.3 μM, and demonstrates that the compounds have significant degradation activity on the estrogen receptor.

[0532] Table 2 :

[0533]

[0534]

[0535] Therefore, it is obvious that the test compound has degradation activity on estrogen receptor, with IC50 less than 1 μM and degradation level greater than 50%. Therefore, the compound of formula (I) can be used for the preparation of drugs, especially drugs as degraders of estrogen receptor.

[0536] Therefore, also provided herein is a medicament comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.

[0537] Also provided herein is a compound of formula (I) as defined above, or a pharmaceutically acceptable salt thereof, for use as a medicament.

[0538] Also provided herein are compounds of formula (I) as defined above, or pharmaceutically acceptable salts thereof, for use in therapy, particularly as inhibitors and degraders of estrogen receptors.

[0539] Also provided herein is a compound of formula (I) as defined above, or a pharmaceutically acceptable salt thereof, for use in the treatment of ovulatory dysfunction, cancer, endometriosis, osteoporosis, benign prostatic hypertrophy or inflammation.

[0540] A particular aspect is a compound of formula (I) as defined above, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer.

[0541] In embodiments, the cancer is a hormone-dependent cancer.

[0542] In another embodiment, the cancer is an estrogen receptor dependent cancer, in particular the cancer is an estrogen receptor alpha dependent cancer.

[0543] In another embodiment, the cancer is selected from breast cancer, ovarian cancer, endometrial cancer, prostate cancer, uterine cancer, cervical cancer, and lung cancer, or metastases thereof.

[0544] In another embodiment, the metastasis is a brain metastasis.

[0545] In another embodiment, the cancer is breast cancer. In particular, the breast cancer is estrogen receptor positive breast cancer (ERα positive breast cancer).

[0546] In another embodiment, the cancer is resistant to anti-hormone therapy.

[0547] In further embodiments, the compounds of Formula (I) are used as single agents or in combination with other agents such as CDK4 / 6, mTOR or PI3K inhibitors.

[0548] According to another aspect, provided herein is a method of treating the above indicated pathological conditions, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. In an embodiment of this method of treatment, the subject is a human.

[0549] Also provided herein is the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament useful for the treatment of any of the above indicated pathological conditions, more particularly useful for the treatment of cancer.

[0550] Also provided herein are pharmaceutical compositions comprising a compound of formula (I) as an active ingredient. These pharmaceutical compositions comprise an effective dose of at least one compound of formula (I) or a pharmaceutically acceptable salt thereof, and also at least one pharmaceutically acceptable excipient.

[0551] The excipients are selected from the customary excipients known to those skilled in the art, depending on the desired pharmaceutical form and method of administration.

[0552] In pharmaceutical compositions for oral, sublingual, subcutaneous, intramuscular, intravenous, topical, local, intratracheal, intranasal, transdermal or rectal administration, the active ingredient of the above formula (I) or its base, acid, zwitterion or salt thereof can be administered to animals and humans in a unit administration form, as a mixture with conventional pharmaceutical excipients for the treatment of the above disorders or diseases.

[0553] Suitable unit administration forms include oral forms such as tablets, soft or hard capsules, powders, granules and oral solutions or suspensions, sublingual, buccal, intratracheal, intraocular and intranasal administration forms, forms for inhalation, topical, transdermal, subcutaneous, intramuscular or intravenous administration, rectal administration forms and implants. For topical application, the compounds of formula (I) can be used in creams, gels, ointments or lotions.

[0554] As an example, a unit administration form of a compound of formula (I) in the form of a tablet may comprise the following components:

[0555]

[0556] There may be specific cases where higher or lower doses are appropriate. According to routine practice, the appropriate dose for each patient is determined by the physician according to the mode of administration and the weight and response of the patient.

Claims

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof: in: - R1 and R2 independently represent a hydrogen atom or a deuterium atom; -R3 represents a hydrogen atom, a -COOH group or a -OH group; - R3' and R3" independently represent a hydrogen atom, a methyl group, a methoxy group, a chlorine atom, a fluorine atom or a cyano group; - R4 and R4' independently represent a hydrogen atom or a fluorine atom; -R5 represents a hydrogen atom, a fluorine atom or a (C1-C3) alkyl group; -R6 represents a group selected from the following: ■ phenyl, which is optionally substituted by 1 to 3 substituents independently selected from the group consisting of a halogen atom; a (C1-C6)alkyl group optionally substituted by a cyano group or an -OH group; a (C1-C6)fluoroalkyl group; a (C3-C6)cycloalkyl group; a (C1-C6)alkoxy group; a (C1-C6)fluoroalkoxy group; a cyano group; a trifluoromethylsulfonyl group; a (C1-C4)alkylthio group; a (C1-C4)fluoroalkylthio group; a (C1-C4)alkylsulfonyl group and an -OH group; ■ a fused phenyl group selected from a phenyl group fused to a (C3-C6)cycloalkyl group, the (C3-C6)cycloalkyl group optionally comprising unsaturation, and wherein the fused phenyl group is optionally substituted with 1 to 3 substituents independently selected from a (C1-C3)alkyl group, a hydroxyl group, a halogen atom, a (C1-C6)fluoroalkyl group, and a (C1-C3)alkoxy group; ■ a bicyclic group containing 5 to 12 carbon atoms, optionally containing 1 to 2 degrees of unsaturation; optionally substituted by 1 to 4 substituents independently selected from the group consisting of fluorine atoms, -OH groups, (C1-C3)alkyl groups, (C1-C3)fluoroalkyl groups, (C1-C3)alkoxy groups, (C1-C3)fluoroalkoxy groups and oxo groups; ■ a heteroaryl group containing 2 to 9 carbon atoms and containing from 1 to 3 heteroatoms independently selected from oxygen, nitrogen and sulfur and at least 5 atoms including carbon atoms and heteroatoms, such as a pyridyl group, which is optionally substituted by 1 to 3 substituents independently selected from halogen atoms, (C1-C6)alkyl, (C1-C6)fluoroalkyl, (C1-C6)alkoxy, (C1-C6)fluoroalkoxy, cyano, carbamoyl and -OH groups; ■ a cycloalkyl group containing 3 to 7 carbon atoms, which is saturated or partially saturated and optionally substituted with 1 to 4 substituents independently selected from: o fluorine atom, -OH group, (C1-C3) alkyl group, (C1-C3) fluoroalkyl group, (C1-C3) alkoxy group, (C1-C3) fluoroalkoxy group, oxo group, o (C3-C6) cycloalkyl and phenyl, wherein the (C3-C6) cycloalkyl or phenyl is optionally substituted by one or two halogen atoms or (C1-C3) alkyl; ■ (C3-C6)cycloalkyl (C1-C3)alkyl, which is optionally substituted on the cycloalkyl by 1 to 4 substituents independently selected from the group consisting of a fluorine atom, an -OH group, a (C1-C4)alkyl group, a (C1-C3)fluoroalkyl group, a (C1-C3)fluoroalkoxy group and an oxo group; ■ 4- to 7-membered heterocycloalkyl containing 1 or 2 heteroatoms independently selected from oxygen, nitrogen and sulfur, such as tetrahydropyranyl, which is saturated or partially saturated and optionally substituted by 1 to 3 substituents independently selected from the group consisting of fluorine atoms, (C1-C3)alkyl, (C1-C3)fluoroalkyl, (C1-C3)fluoroalkoxy, oxo, (C1-C3)alkoxy and -OH groups; ■ (C1-C6) alkyl, such as isobutyl, methyl or ethyl, optionally substituted with 1 to 4 substituents independently selected from the group consisting of fluorine atoms, (C1-C3) alkoxy, (C1-C3) fluoroalkoxy and -OH groups; and ■phenyl(C1-C2)alkyl, the phenyl being optionally substituted by 1 to 3 substituents independently selected from the group consisting of: halogen atoms; (C1-C3)alkyl; (C1-C3)fluoroalkyl; (C1-C3)alkoxy; (C1-C3)fluoroalkoxy; cyano; and -OH groups; -X represents -CH2-, -O- or -S-; -Y represents -CH=, -N= or -CR"=, wherein R" represents a (C1-C3)alkyl group, a halogen atom such as a fluorine or chlorine atom, a cyano group, or a (C1-C3)fluoroalkyl group such as a trifluoromethyl group; - R7 independently represents a (C1-C3)alkyl group such as a methyl group, a halogen atom such as a fluorine atom, a cyano group, or a (C1-C3)fluoroalkyl group such as a trifluoromethyl group; -R8 represents a hydrogen atom or a fluorine atom; -R9 represents a hydrogen atom, a (C1-C3) alkyl group or a cyclopropyl group; -n is 0, 1, or 2; and -m is 0 or 1.

2. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1, characterized in that: R1 and R2 are hydrogen atoms.

3. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1 or 2, characterized in that: R3 is a -COOH group.

4. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 3, characterized in that: R3' and R3" both represent a hydrogen atom.

5. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4, characterized in that: R4 and R4' both represent a hydrogen atom; or one of R4 and R4' represents a hydrogen atom and the other represents a fluorine atom.

6. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 5, characterized in that: X represents -CH2-.

7. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 6, characterized in that: R5 represents a hydrogen atom.

8. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 7, characterized in that: R6 represents a phenyl group, which is optionally substituted by 1 to 3 substituents independently selected from the following: a halogen atom; a (C1-C6) alkyl group and a (C1-C6) fluoroalkyl group, more particularly selected from a chlorine atom, a fluorine atom, a methyl group and a trifluoromethyl group.

9. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 8, characterized in that: n is 0 or 1 and R7 is a fluorine atom.

10. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 9, wherein: Y represents -CH=.

11. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 10, wherein: m is 1.

12. A compound of formula (I) or a pharmaceutically acceptable salt thereof, in particular a hydrochloride thereof, according to any one of claims 1 to 11, characterized in that The compound is selected from the following compounds: -(Z)-8-(2,4-dichlorophenyl)-9-(4-((1-(3,3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride (1), -(Z)-8-(2-chloro-4-fluorophenyl)-9-(4-((1-(3,3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid (2), -(Z)-4-(2,4-dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-2,3-dihydrobenzo[b]oxepin -8-carboxylic acid hydrochloride (3), -Z)-8-(2,4-dichlorophenyl)-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid (4), -(Z)-8-(2,4-difluorophenyl)-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride (5), -(Z)-8-(4-fluoro-2-methylphenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid (6), -(Z)-3-(4-(8-(2-chlorophenyl)-6,7-dihydro-5H-benzo[7]annulene-9-yl)benzylidene)-1-(3-fluoropropyl)pyrrolidine (7), -(Z)-8-(4-fluoro-2-(trifluoromethyl)phenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid (8), -(Z)-8-(2,4-difluorophenyl)-9-(4-((1-(3,3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid (9), -(Z)-8-(3-chloro-2-methylphenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid (10), -(Z)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-8-(3-methyl-2-(trifluoromethyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid (11), -(Z)-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-8-(3-methyl-2-(trifluoromethyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid (12), -(Z)-8-(3-chloro-2-methylphenyl)-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid (13), -(Z)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-8-(2-methyl-3-(trifluoromethyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid (14), -(Z)-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-8-(4-fluoro-2-methylphenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid (15), -(Z)-8-(2,4-dichlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-ol hydrochloride (16), -(Z)-8-(2,4-dichlorophenyl)-9-(4-((1-(3-difluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-ol hydrochloride (17), -(Z)-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-8-(4-fluoro-2-(trifluoromethyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid (18), -(Z)-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-8-(2-methyl-3-(trifluoromethyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid (19), -(Z)-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-8-(4-fluoro-2,6-dimethyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid (20), -(Z)-8-(4-fluoro-2,6-dimethylphenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid (21), -(Z)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-8-(2-(trifluoromethyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid (22), -(Z)-8-(2,4-dichlorophenyl)-9-(3-fluoro-4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid (23), -(Z)-6-(2,4-dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-7,8-dihydronaphthalene-2-carboxylic acid hydrochloride (24), -(Z)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-8-(3-(trifluoromethyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid (25), -(Z)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-8-(4-(trifluoromethyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid (26), -(Z)-8-(3-chlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid (27), -(Z)-8-(4-chlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid (28), -(Z)-8-(4-fluoro-2,5-dimethylphenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid (29), -(Z)-4-(2,4-dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-2,3-dihydrobenzo[b]thia -8-ol (30).

13. A method for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 12, wherein: The compound of formula 1K wherein R1, R2, R3′, R3″, R4, R4′, R5, R6, R7, R8, R9, m, n, X and Y are as defined in any one of claims 1 to 11, and R3a is a hydrogen atom, a carboxylate such as COOMe, COOEt, or a protected OH such as O-pivaloyl - is converted into a compound of formula (I) in solution in methanol in the presence of a hydroxide ion source such as NaOH or LiOH, said step optionally being preceded by a step for obtaining compound 1K, wherein a compound of formula 1P is converted into a compound of formula (I) in solution in methanol in the presence of a hydroxide ion source such as NaOH or LiOH, said step optionally being preceded by a step for obtaining compound 1K -- wherein R1, R2, R3', R3", R4, R4', R5, R7, R8, R9, m, n, X and Y are as defined in any one of claims 1 to 11, and R3a is as defined above-- Subjected to Suzuki coupling with a boronic acid reagent R6B(OR')2 or R6BF3K, wherein -B(OR')2 is a boronic acid or pinacol ester and R6 is as defined in claim 1 or 8.

14. A method for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 12, wherein: The compound of formula 1Pa - wherein R1, R2, R3', R3", R4, R4', R5, R7, R8, R9, m, n, X and Y are as defined in any one of claims 1 to 11 and R3a is as defined in the preceding claim - undergoing Suzuki coupling with a boronic acid reagent R6B(OR')2 or R6BF3K - wherein -B(OR')2 is a boronic acid or a pinacol ester and R6 is as defined in claim 1 or 8 -, said step optionally being preceded by a step for obtaining compound 1Pa, wherein a compound of formula 1P -- wherein R1, R2, R3', R3", R4, R4', R5, R7, R8, R9, m, n, X and Y are as defined in any one of claims 1 to 11, and R3a is as defined above-- The conversion to compound 1Pa is carried out in solution in methanol in the presence of a hydroxide ion source such as NaOH or LiOH.

15. A compound selected from the group consisting of compounds of formula 1P, 1K and 1Pa or any pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R3', R3", R4, R4', R5, R7, R8, R9, m, n, X and Y are as defined in any one of claims 1 to 11, and R3a is a hydrogen atom, a carboxylate such as COOMe, COOEt, or a protected OH such as O-pivaloyl.

16. A compound of formula 1F or formula 1D or any pharmaceutically acceptable salt thereof wherein R1, R2, R4, R4', R5, R7, R8, Y and n are as defined in any one of claims 1 to 11.

17. A drug, characterized in that The medicament comprises a compound of formula (I) according to any one of claims 1 to 12 or a pharmaceutically acceptable salt thereof.

18. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises a compound of formula (I) according to any one of claims 1 to 12 or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient.

19. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 12 for use as an inhibitor and degrader of estrogen receptors.

20. A compound of formula (I) according to any one of claims 1 to 12 or a pharmaceutically acceptable salt thereof for use in the treatment of ovulatory dysfunction, cancer, endometriosis, osteoporosis, benign prostatic hypertrophy or inflammation.

21. A compound of formula (I) or a pharmaceutically acceptable salt thereof for use according to claim 20, for use in the treatment of cancer.

Citation Information

Patent Citations

  • 6,7-dihydro-5h-benzo[7]annulene derivatives as estrogen receptor modulators

    WO2017140669A1

  • Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof

    WO2018091153A1

  • Process for the preparation of methyl 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-YL]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylate

    WO2020049153A1